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1Chapter I:  General Introduction
Introduction
The production and sale of beef and dairy products claiming to be organic (that is, 
produced with the intention of ecological responsibility) have grown steadily since 
the early 1990s.  In the decade between 1995 to 2005, organic beef farming 
experienced over a nine fold increase in organic beef cattle from about 4,000 head 
to over 36,000 head, while organic dairy farming witnessed a seven fold increase in 
organic dairy cattle from around 12,000 head to over 87,000 head(1).  However, a 
food that is certified organic does not guarantee any differences in nutrient 
composition as compared with conventional foods.  In contrast, the practice of 
pasturing beef and dairy cattle (that is, letting them graze on pastures for nearly all 
of their food intake) has been shown to cause noteworthy changes in the nutrient 
composition of the resulting products, particularly in the fatty acid composition: 
increasing the length of pasturing and decreasing the consumption of prepared 
feeds increases the presence of trans fatty acids, the amount of polyunsaturated 
fatty acids, and the ω3:ω6 fatty acid ratio(2).  The most pronounced difference 
between beef and dairy products from grain-fed versus pasture-fed cattle is the 
content of a series of diunsaturated fatty acids known as conjugated linoleic 
acids(2).
Conjugated linoleic acid (CLA) has been both positively and inversely correlated with 
2changes in the risk factors associated with cardiovascular diseases, diabetes, liver 
necrosis, body composition, and a number of other conditions to be reviewed in the 
following chapter.  Many of the studies on CLA have been conducted using 
supplements with isomeric compositions that do not mimic those found in the natural 
food supply, that contain super-dietary concentrations, or are provided to free-living 
humans, conditions that do not account for a number of other potentially 
confounding factors such as isomer specific effects, natural consumption patterns, or 
differences in caloric intake.  To date, no studies have compared the effects of 
products from pasture-fed cattle versus similar products from feedlot cattle, and 
therefore certainly none have compared products naturally high in CLA from pasture-
fed sources versus naturally CLA deficient products from feedlot sources.
The boom in consumers choosing “natural” and “organic” products on the auspices 
of purported improved health means that research must be conducted to determine 
the actual effects these products have on human beings.  Further, the increasing 
number of advertisements for CLA supplements appearing on shelves, and the 
popular use of CLA for marketing by pasture-fed beef and dairy producers creates a 
demand for scientific literature elucidating the effects these products have on 
consumers.  Mass media may be considered the largest source of nutritional 
information for the average consumer, and the information is frequently reported not 
by knowledgeable scientists or dietitians, but journalists.  In one example, Time 
Magazine ran a story entitled “The Grass-Fed Revolution,” in which conventional 
agriculture was described as detrimental to health while grass-fed beef and dairy 
3products were praised(3).  Sadly, none of the information presented in the story 
amounted to any scientific evidence that grass-fed products were healthier than 
conventional products because no scientific evidence exists to date to establish that 
link.  Rather, present evidence indicates that beef and dairy products from pastured 
cattle have what is generally considered to be improved fatty acid characteristics, 
such as the previously mentioned increase in polyunsaturated fatty acids, improved 
ω3:ω6 fatty acid ratio, and increase in CLA content; it is then assumed that these 
changes will result in improved health, potentially resulting in spurious correlations. 
The scientific evidence for the effects of CLA on health, unlike products from 
pasture-fed animals, is much more well researched.  However, the scientific 
literature overall is inconclusive.  The varied responses to CLA supplementation 
range from improved health, to maintaining status quo, to even impairing health. 
With no evidence comparing beef and dairy products from pasture-fed versus grain-
fed cattle, and a body of controversial evidence on the effects of CLA, the present 
study was designed to look at the effects that products naturally rich in CLA have on 
female volunteers as compared with products naturally deficient in CLA.
Organization of thesis
After this general introduction, a comprehensive review of the present literature on 
CLA is to follow in Chapter II.  The literature review will focus on aspects of CLA 
related to the study that will be presented in Chapter III, including the history of CLA 
as it exists in scientific literature, early research on and the discovery of CLA, 
4methods of production, purported health effects, and theoretical mechanisms of 
physiological action.  Chapter III will present original research conducted at Iowa 
State University on the effects of products naturally rich in CLA from beef and dairy 
products from pasture-fed cattle against those from grain-fed cattle.  The study will 
be presented in journal format, modeled after the American Journal of Clinical 
Nutrition format.  Chapter IV will include a general discussion of CLA and the 
presented research, as well as general conclusions about CLA and the presented 
research, after which recommendations for future research will be discussed.  In the 
appendix, a study that examines the safety of the use of sucralose to help maintain 
participant adherence to experimental protocols will be presented.  This thesis will 
then conclude by acknowledging the many individuals that contributed to make this 
work possible, followed by recognition of the materials referred to throughout the 
thesis, as denoted by numbers between parentheses.
5Chapter II:  Review of Literature
Introduction
Health and nutrition research related to lipid consumption has focused on a variety 
of topics, from total lipid intake and macronutrient composition of diets, to the 
consumption of individual fatty acids.  While total lipid intake and dietary 
macronutrient consumption is still a prominent focus of research, lipid nutrition has 
evolved to focus on the impacts of certain classifications of fatty acids, such as 
saturated fatty acids (SFAs), monounsaturated fatty acids (MUFAs), polyunsaturated 
fatty acids (PUFAs), omega-3 (ω-3) fatty acids, and omega-6 (ω-6) fatty acids, to 
name a few.  Of late, a variety of research has been conducted on a fairly small and 
relatively specific grouping of fatty acids known as conjugated linoleic acids (CLA).
CLA refers to a group of octadecadienoic acids in which the two double bonds are 
separated by only one single bond.  The structure of the bonds lends the word 
conjugated to the series name, whereas linoleic acid is actually a misnomer: linoleic 
acid is c9,c12-octadecadienoic acid.  The name, however, is now well indoctrinated 
into scientific lexicon and recognized in the field of lipid nutrition, misnomer or not.
In this review of literature, the production of CLA, the potential health benefits of CLA 
consumption, and the mechanisms of CLA's actions will be considered.
6CLA Production
Mechanisms in Animals  
Dietary CLA can be derived from a number of animals, but the most proficient 
producers, and certainly the most relevant to human nutrition, are ruminant animals. 
Rumen hydrogenation of unsaturated fatty acids has been reported and researched 
for decades.  In 1954, Hartman and colleagues found fatty acids containing trans 
double bonds in considerable quantities (3.5-11.2% of fatty acids present) in 
ruminant tissues, whereas non-ruminant tissues contained only trace amounts(4). 
The pastures on which the ruminant animals were grazing did not contain an 
appreciable amount of trans fatty acids, so the difference between the animals' 
dietary lipid composition and physiological lipid composition was theorized to be the 
result of previously reported rumen biohydrogenation(4).  Other studies in the 1950s 
elucidated that not only does the rumen hydrogenate linolenic acid (c9,c12,c15 
octadecatrienoic acid), the most common dietary fatty acid of pastured ruminants, to 
linoleic acid, but that hydrogenation can proceed to full saturation(5).  Furthermore, 
Shorland and colleagues showed that the fatty acid composition of clover fields on 
which sheep were grazing did not match the composition of the sheeps' rumen 
contents.  Concerned that this may merely reflect the catabolism of the lipids, 
linolenic acid was added to an artificial rumen; subsequently, SFAs, MUFAs, 
conjugated and non-conjugated dienes and trienes, and trans double bonds were 
detected, all of which are evidence of rumen biohydrogenation(5).  These alterations 
7partially explained the discrepancy that existed between the fatty acid content of the 
diets of ruminants and the fatty acid profiles of their milk and meat.
One of the earliest mechanisms to explain the presence of conjugated dienes in 
butter was theorized by Bartlet and Chapman in 1961, in which linoleic acid was 
thought to isomerize to a cis-trans conjugated diene before either being absorbed or 
being hydrogenated to a trans monoene; the trans bond formed in the isomerization 
step was thought to be the rate limiting step(6).  Research on one particular microbe, 
Butyrinvibrio fibrisolvens, led to the confirmation of Bartlet's and Chapman's 
hypothesis of biohydrogenation(7).  Presently, it is thought that PUFAs are toxic to 
many rumen microbes, and that hydrogenation is, in effect, a way of detoxifying the 
rumen(8)(9).  The production of CLA in the rumen is a sign of toxic conditions for the 
rumen microbes, which would decrease cellulose metabolism and rumen growth 
performance if conditions became overbearing(9).
Rumen biohydrogenation is responsible, directly or indirectly, for the production of 
many isomers of CLA, such as the c9,t11, t7,c9, and c7,t9 isomers commonly found 
in beef(10) and dairy(11) products, as well as the production of 14 other naturally 
produced trace isomers(12).  However, the isomeric profiles of ruminant milk and 
meat products do not match the isomeric profile expected from rumen 
biohydrogenation alone, which is evidenced by a large discrepancy in the fatty acid 
profiles of duodenal contents and milk from lactating dairy cows(13).  While the 
8duodenal contents contain a low amount of CLA, the milk shows a much higher 
content, and a vastly different CLA isomeric profile dominated by c9,t11 CLA.  Other 
mechanisms must therefore exist to convert absorbed biohydrogenation products 
into CLA.
One of the most abundant biohydrogenation products from the rumen are trans 
octadecenoic fatty acids, and particularly the t11 isomer, known as trans vaccenic 
acid (tVA)(7).  The endogenous desaturation of tVA by a Δ9 desaturase, known as 
steroyl-CoA desaturase (SCD), results in the production of c9,t11 CLA(13).  The 
production of tVA in large amounts via biohydrogenation results in an 
overabundance of this byproduct, which is then desaturated in extrarumenic tissues; 
however, not all of the tVA is desaturated, resulting in tVA in milk and meat.  For 
instance, Backderf and Brown reported that butter contains approximately 4% of its 
fatty acid content as tVA(14).  Humans, too, have SCD, which endogenously 
converts consumed tVA to CLA(15), and thus the final CLA content in a human after 
consuming ruminant products is not a direct reflection of the CLA consumed.
Effects of Ruminant Diet on CLA Production  
Ruminant animals fed on pasture have a higher proportion of their fatty acids as 
PUFAs as compared with grain-fed animals.  In particular, ruminant animals grazing 
on pastures consume much more linolenic acid, as well as a rich supply of linoleic 
and oleic acids.  Thus, more partial hydrogenation results in the rumen when 
9compared to the standard grain diet, and, further, an increase in grazing period prior 
to slaughter results in an increase in CLA content in the meat: one study showed a 
linear CLA content increase of 150% in muscle tissue and 250% in subcutaneous 
adipose tissue when grazing periods were varied from 0 days of grazing to 158 days 
of grazing prior to slaughter(16).  The effect of grass feeding has been confirmed by 
at least one other study(17).
Other alterations in the ruminant diet may also lead to increased concentrations of 
CLA in the products from these animals.  Supplementing grain diets with different 
oils, for instance, can cause a change in CLA content of the meat.  Sunflower 
enriched diets result in approximately a three fold increase in CLA(2), linseed 
enrichment results in a two fold increase(2), and supplementation with a 2:1 mix of 
sunflower oil and fish oil results in almost a ten fold increase(18).  The resulting CLA 
has been reported as being natural in some literature, though whether cattle 
consuming fish oil and flax is natural is debated.
Most of the CLA produced naturally through biohydrogenation and subsequent 
desaturation is in the form of the c9,t11 isomer.  Increasing the amount of some oils 
in the diet, such as fish oil, results in an increase in the t10,c12 isomer of CLA, which 
has been implicated as a product of rumen dysfunction(12); caution must therefore 
be used when attempting to use cattle as CLA mills.
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Commercial CLA Preparations  
The amount of dietary fats and oils a ruminant converts to CLA is a rather small 
percentage, accounting for up to only a few percent of the total lipid in ruminant 
products(2)(16)(18).  Because of the interest in CLA, commercial methods have 
been developed in which polyunsaturated oils are converted to CLA mixtures 
through a series of acid and alkali reactions.  In early research, the composition of 
the CLAs created through these processes resulted in unnatural ratios of a number 
of CLA isomers.  Christie and colleagues reported that some commercial CLA 
supplements contain all trans CLAs, all cis CLAs, and, in one sample, found the 
positional isomers of 8,10 : 9,11 : 10,12 : 11,13 in a ratio of 14:30:31:24, though the 
geometric isomerization of each positional isomer was unknown (that is, the 8,10 
positional isomer could have contained c8,c10, c8,t10, t8,c10, and/or t8,t10)(19). 
Most analyses simply assumed the two major peaks were the two most common 
CLA isomers in commercial preparations: c9,t11 and t10,c12(19).  Further advances 
in the reaction and purification steps allowed for large scale production of purified 
mixed isomer CLAs, as well as specific isomeric ratios of CLA, including the alkali 
isomerization of various oils, urea crystallization for purity, or interesterification into 
triacylglycerols (TAG)(20).  
The bioavailability of these commercially synthesized CLAs has been in question 
because the responses to mixtures of CLAs administered in different food matrices 
or pill supplements to humans have varied vastly from animal models, which will be 
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reviewed later.  The synthetic production of CLA is generally used to produce free 
fatty acids, specific esters, or TAG, all of which do not mimic the natural composition 
of lipids consumed in the diet.  As an example, TAG generally contain their most 
unsaturated fatty acids on the SN2 position of the glycerol backbone, while the SN1 
and SN3 positions contain the most saturated fatty acids.  Gastric and pancreatic 
lipases, therefore, react differently to TAG that contain a different pattern of 
saturation.
Effects of CLA on Markers of Health
Studies have been conducted on the effects of CLA on markers of health in cell 
models, tissue cultures, animal models, and humans, with varying results.  Some 
variation in results can be accounted for by noting the differences in isomers used in 
each study, or in the appropriateness of the model being applied to humans. 
Variation also exists in whether the CLA preparation is fed ad-libitum, as part of a 
controlled diet, or as a supplement.  Furthermore, some researchers have concluded 
that because their research shows no biological effects in their sample populations 
that CLA has no effect in the total population, regardless of trends toward 
significance or the inappropriateness of extrapolating from one population to 
another.  The compounding of these confounding factors results in a very muddled 
view of the effects of CLA on various markers of health.
One of the first studies attributed to studying the effects of CLA was conducted by 
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Pariza and others on pan-fried hamburger(21).  Concerns over mutagenic properties 
of fried hamburger led the investigators to test extracts of the hamburgers using the 
Ames test and rats, in which they found that CLA actually decreased mutagenesis. 
This report is often considered the first on the potential health benefits of CLA, and 
much research has ensued in the following decades.
Body Composition  
Obesity and overweightness have become increasing concerns world wide in 
developing and developed countries alike.  The CDC reports that the National Health 
and Nutrition Examination Survey (NHANES) from 1976 to 2004 has shown an 
increase in obesity from 15.0% to 32.9% of adults in the United States(22).  Obesity 
has been implicated in approximately 112,000 excess deaths as compared with 
normal weight individuals(23), and the co-morbidities associated with obesity include 
diabetes, hypertension, and a host of other problems(22).  Anything that can be 
associated with a reduction in obesity, therefore, is researched heavily, and CLA is 
no exception.
Animal studies have shown alterations in body composition, such as a decrease in 
body fat mass and an increase in lean mass, associated with CLA supplementation 
in mice(24)(25), hamsters(26)(27), and rats(28)(29)(30).  Differing effects of 
individual CLA isomers were demonstrated in animal models, with evidence that the 
t10,c12 isomer is the bioactive isomer in relation to body composition(27).  However, 
13
the results are not uniform in different animal genetic models: genetically diabetic 
and obese Zucker rats did not respond to CLA while their non-obese counterparts 
did respond(29).  Results such as these spurred human research on the effect of 
CLA supplementation on human body composition.
As with the Zucker rats, BMI class may or may not play a factor in the ability of CLA 
supplementation to result in body compositional changes in humans.  Using dual-
energy x-ray absorptiometry (DXA), Laso and colleagues showed that consumption 
of 3 g/d of a 50:50 mixture of c9,t11 and t10,c12 CLA isomers resulted in a 2% 
decrease in total body fat mass with a 3% decrease in trunk fat mass in a 12 week 
trial in overweight subjects (25<BMI<30), while the obese subjects (30<BMI<35) 
showed no such differences(31).  Consistent with these results, a group of men and 
women, most of whom had a BMI of normal to overweight (18<BMI<30), lost 3.8% of 
their body fat mass after CLA supplementation(32).  In another study, Steck and 
colleagues reported that supplementation with 6.4 g/d CLA resulted in an increase in 
lean mass of 0.64 kg over a 12 week period in obese subjects, but again no changes 
were recorded in the fat mass of the obese participants.  They also saw no effects 
with only 3.2 g/d CLA(33).  In yet another group of obese participants, who were 
subjected to a weight loss regimen and then supplemented with 3.4 g/d of CLA or a 
placebo for one year to test total- and fat-mass regain, no differences were seen 
between the two treatments(34).  Consistent with the other obesity studies, 
abdominally obese men, either supplemented with mixed CLA isomers or purified 
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t10,c12 CLA, showed no differences in abdominal adiposity, body weight, or body fat 
mass as compared with a placebo(35).  However, contrary to Laso and others' 
results, supplementing middle aged males with a BMI in the range of normal to 
overweight (18<BMI<30) with 1.4 g/d c9,t11 incorporated into dairy products by 
modified feeding resulted in no change in body weight or BMI(18).  Thus, no 
consistent results related to CLA supplementation are seen in individuals of different 
BMI classes.
Type and amount of exercise in conjunction with CLA inconsistently alters the results 
of supplementation.  In one study, 20 participants exercised in a gym for 90 min 
three times per week and were either given a placebo or 0.6 g/d of CLA in capsule 
form.  The participants supplemented with CLA showed decreased adiposity as 
compared with the placebo group, but neither group had a difference in body 
weight(36).  CLA supplementation of 3.6 g/d, both in conjunction with directed 
exercise or with supplementation alone, improved body composition and decreased 
body weight in young females(37).  In other studies, participants engaged in 
strength-training receiving 6 g/d of CLA supplementation against a placebo did not 
show differences in any markers of body composition(38).  In free living humans, the 
alterations in body composition seen with CLA supplementation were determined not 
to be the result of the amount of exercise in which the individuals were engaged(39)
(40).  In adult males and females who reported being physically active on their own 
volition, 3.9 g/d of CLA supplementation resulted in no change in body composition 
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or distribution as measured by DXA(41).  It does not appear, then, that exercising in 
conjunction with CLA supplementation has a definitive synergistic effect on body 
composition.
The most convincing evidence to date that CLA effects body composition is a meta-
analysis of 18 double-blind, placebo-controlled studies that indicated CLA 
consumption results in a dose-dependent response, with an approximate efficacy 
equation of -24 g of body fat each week for each gram of CLA consumed; the 
analysis also reported an approximate linear response for 6 months followed by a 
decline in response until body fat stabilizes after 2 years(42).  This would imply that 
chronic CLA supplementation may, at best, have a modest effect on body 
composition.
Glucose Intolerance and Insulin Resistance  
Insulin, in a generic description, is the hormone primarily responsible for the 
postprandial distribution and storage of energy-containing macronutrients. 
Impairment of insulin sensitivity can result from a host of maladies related to energy 
homeostasis.  Research investigating the effects of CLA supplementation on animal 
models of insulin resistance have shown mixed results.  Obese mice showed 
impaired insulin sensitivity upon supplementation with CLA (43), as did normal male 
mice(44) and hamsters(26).  However, in obese rats, CLA was shown to decrease 
circulating glucose and insulin concentrations, both markers of improved glucose 
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tolerance(30)(45).
In humans, inconsistent results are demonstrated as well.  One variable to explain 
the inconsistencies is sex, where insulin sensitivity seems to be improved in females 
as compared to males.  Supplementation with 3.6 g/d mixed isomers of CLA resulted 
in an improvement in glucose tolerance in a group of young females(37), while 5.5 g/
d mixed isomers resulted in no differences in markers of glucose tolerance in young 
men(46).  In non-obese men and women who exercised regularly, only women had 
lower mean insulin concentrations in an oral glucose tolerance test, whereas the 
men showed no change(41).  Supplementation of 1.4 g/d of c9,t11 CLA in middle-
aged men did not alter circulating glucose or insulin concentrations(18), nor did 
supplementation with three different doses of either c9,t11 or t10,c12 isomers of CLA 
result in differences in a number of insulin resistance measurements in another 
group of healthy men(47).  In contrast to the trend of men being unaffected by CLA, 
abdominally obese men supplemented with 3.4 g/d of the t10,c12 CLA isomer 
actually increased insulin resistance; however, with 3.4 g/d of mixed isomer 
supplementation, no change was seen in insulin sensitivity(35).  In a mixed-sex 
group of nine overweight, non-diabetic subjects, insulin sensitivity was decreased 
after supplementation with 4 g/d of mixed isomers of CLA(48), which, at least 
superficially, appears to conflict with the other literature mentioned.  Though the 
trend would seem to be that females are more responsive to the insulin sensitizing 
capabilities of CLA supplementation, very few studies have directly compared the 
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effects between the two sexes, and so the stated trend may be considered 
speculative; further, there are conflicting reports regarding isomeric effects, and 
there is also a potential interaction with body mass classification.
Often, insulin resistance brings thoughts of diabetes to mind.  Very little research has 
been conducted in diabetic subjects, however.  In the only study to date to 
investigate the effects of CLA on glucose metabolism in subjects with type II 
diabetes mellitus, Moloney and colleagues reported an increase in fasting glucose 
concentrations by over 6% after treatment with 3.0 g/d 50:50 mixed isomer CLA 
supplementation against a placebo.  In addition, they demonstrated that 
supplementation resulted in impairment of several insulin resistance indices(49). 
With such gloomy results, it may be prudent not to pursue CLA research in diabetic 
subjects until its effects are further understood.
Coronary Heart Disease Risk  
The American Heart Association reports that the alterable risk factors for 
cardiovascular diseases (CVD) are elevated serum cholesterol concentrations, 
increased blood pressure, smoking, physical inactivity, obesity, and diabetes(50). 
Because there is no known reason that CLA supplementation should decrease 
smoking or increase physical activity upon supplementation, these two risk factors 
will not be addressed here within.  Alterations in body composition and insulin 
resistance have already been addressed separately, so only cholesterol 
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concentrations and blood pressure will be addressed here.
Circulating cholesterol concentrations have been associated with CVD(51). 
Lipoproteins, the circulating particles that are primarily comprised of apolipoproteins, 
cholesterol, TAG, and phospholipid, have been differentially correlated with CVD 
depending on the density class to which they belong.  The lower density lipoproteins, 
which contain apolipoprotein B, or ApoB, have been positively associated with 
CVD(51).  ApoB-containing lipoproteins include very low-density lipoproteins (VLDL; 
density <1.006 g/mL), intermediate-density lipoproteins (IDL; density >1.006 and 
<1.019 g/mL) and low-density lipoproteins (LDL; density >1.019 and <1.063 g/mL). 
Of VLDL, IDL, and LDL, IDL has recently been recognized as one of the most 
atherogenic lipoprotein classes, though elevated VLDL and LDL concentrations have 
still been named as culprits(52).  High-density lipoproteins (HDL), on the other hand, 
are generally considered anti-atherogenic, and decrease the risk of CVD(51). 
Between two subclasses of HDL (HDLII; density >1.063 and <1.125 g/mL.  HDLIII; 
density >1.125 and <1.21), the HDLII fraction is considered more beneficial in 
preventing atherogenesis(53).  If CLA can increase HDL while decreasing ApoB 
containing lipoproteins, and in particular increase HDLII and decrease IDL, then 
theoretically CLA supplementation would decrease the incidence of cardiovascular 
diseases.
Male Sprague Dawley rats fed differing concentrations of CLA had decreased total 
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cholesterol (TC) concentrations and an improved HDL:TC ratio; even though HDL 
was significantly decreased, the improved ratio of HDL:TC indicates that an even 
greater decrease in LDL occurred as well(54).  Similar results were seen in an 
atherosclerosis-prone mouse model(55)(56), thus inspiring human research.
Some human research was able to reproduce the beneficial effects shown in some 
animal models.  In diabetic individuals, a 50:50 mix of CLA isomers supplemented at 
3.0 g/d resulted in an 8% increase in HDL cholesterol, primarily in the HDLII fraction, 
and decreased the LDL to HDL ratio, both considered improvements in blood lipid 
profiles(49).  Other subjects showed improved lipid profiles, as well, throughout two 
years of CLA supplementation including a decrease in TC and LDL(57).
Not all studies reported that CLA improves CVD risk factors, though.  In fact, a study 
in overweight and obese men showed that the placebo resulted in a more significant 
decrease in TC and TC:HDL than did CLA(58).  Another study demonstrated a 
decrease in both HDL and TC concentrations, but not LDL, indicating the majority of 
the TC decrease was the result of the decrease in HDL, theoretically leading to an 
increased risk of CVD(59).  One suggestion for the difference in results is a dose-
dependent and isomer-specific response that was noted in healthy men 
supplemented with individual isomer capsules for 8 weeks: t10,c12 CLA increased 
TC, primarily through the raising of LDL, whereas c9,t11 CLA did not show the same 
results(47).
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To make matters less definitive, a number of studies in humans have shown no 
changes in circulating cholesterol concentrations.  Supplementation with 3.6 g/d with 
or without exercise did not change circulating TAG, TC, HDL, or LDL concentrations 
in young females(37).  In a group of participants with LDL phenotype B (high 
concentrations of small, dense LDL particles), CLA supplementation did not affect 
LDL or HDL concentrations(60).  Other research has shown no effects of CLA on 
blood lipids, either(41)(61).  In summary, the variables dictating the differences in 
cholesterol response to CLA supplementation have not been fully elucidated.
Besides cholesterol concentrations, blood pressure and arterial elasticity are other 
markers of arterial health.  Increases in blood pressure are often observed at the 
onset of obesity, and the Zucker diabetic obese rat is no exception.  Upon 
supplementation with CLA, however, the obesity-related high blood pressure was 
attenuated in these rats(45).  Human studies, again, result in varying responses. 
Raff and colleagues demonstrated that supplementation with 4.7 g/d of a 50:50 
mixture of CLA isomers resulted in no change in arterial health(62), while another 
study on supplementing CLA and calcium to pregnant women decreased pregnancy-
induced hypertension(63).  Japanese, overweight, male volunteers did not show any 
alterations in blood pressure with supplementation(64).  Therefore, it appears that 
how CLA supplementation may decrease blood pressure has yet to be determined.
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Liver health and function
A report of CLA causing hepatomegaly in animal models(65) has led to concern over 
CLA supplementation and liver function in humans.  Two correlates of liver integrity 
that can be measured from blood samples are aspartate aminotransferase (AST) 
and alanine aminotransferase (ALT)(66).  These two enzymes function primarily in 
the liver and are only released into the circulation upon hepatocyte lysis.  Thus, an 
increase in circulating AST and ALT activity generally indicates an increase in liver 
necrosis.  Furthermore, chronic liver diseases may be comorbities associated with 
increased BMI, insulin resistance, and dyslipidemia(66), all of which have been 
correlated to CLA supplementation.
Human studies on the effects of CLA on liver function as measured by AST and ALT 
have not shown anything concerning to date.  Studies 6 weeks(61), 12 weeks(67), 
and 12 months(68) in duration have resulted in no changes in AST and ALT activities 
between CLA supplementation and controls, indicating that CLA does not seem to 
affect liver integrity in acute or chronic CLA supplementation.
Mechanism of action
The questionable safety of CLA has resulted in multitudes of research regarding the 
mechanisms in which CLA may cause its effects.  For instance, if CLA does indeed 
result in a change in body composition, does CLA cause altered lipid metabolism or 
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simply affect the desire to consume energy?  What are the causes for the increases 
and decreases in insulin sensitivity?  And on what does CLA act to cause such 
changes?
Because CLA is a fatty acid, it is appropriate that much of the research to define the 
mechanisms of CLA's action focus on lipid related genes.  Peroxisome proliferator-
activated receptor gamma (PPARγ) is an adipocyte-specific transcription factor that 
dimerizes with the retinoid x receptor (RXR), which together, when activated, can 
upregulate or suppress certain target genes related to lipid metabolism and energy 
homeostasis(69).  Of interest are the upregulation of adipocyte fatty acid binding 
protein (aP2), which is responsible for intracellular binding of fatty acids; acyl-CoA 
synthetase (ACS), which creates a fatty acyl-Coenzyme A thioester; fatty acid 
transporter protein (FATP), which transports fatty acids across the cellular 
membrane; leptin, which is a hormone generally associated with suppressing 
appetite; adiponectin, which can increase hepatic insulin sensitivity, among other 
effects; and lipoprotein lipase (LPL), the enzyme that hydrolyzes TAG from 
circulating lipoprotein molecules(69).  The regulatory activities of PPARγ are 
activated by certain fatty acids, including CLA, as well as fatty acid metabolites such 
as eicosanoids(48)(69).  Recently, Zhou and others found that CLA supplementation 
in an obese rat model upregulated the mRNA expression of PPARγ and some of its 
target genes, such as aP2, FATP, ACS, and adiponectin(30).  In another set of 
studies conducted on human preadipocytes, an isomer specific response was noted; 
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in particular, c9,t11 CLA increased PPARγ expression, whereas the t10,c12 isomer 
decreased PPARγ expression(70).  Furthermore, t10,c12 CLA was able to result in 
delipidation of adipocytes, whereas the c9,t11 isomer was not(71).
To determine the organismal ramifications of the purported changes in PPARγ 
expression, adipokines, which are bioactive adipocyte secretions, were measured in 
several models.  Circulating leptin concentrations are negatively associated with 
energy intake: the higher the circulating leptin, generally the less likely the organism 
is to consume energy.  Like most adipokines, leptin is generally expressed in higher 
concentrations with the more adipose tissue present in the organism.  One would 
then expect that with the depletion of adipose tissue seen in some studies, and the 
isomer specific delipidation of adipocytes previously described, that leptin 
concentrations would decrease upon CLA supplementation.  In contrast, adipocyte 
models show an increase in leptin expression(71), while leptin was not altered upon 
mixed isomer CLA supplementation in a normal male mouse model(44).  Likewise, a 
number of studies have found no differences in leptin concentrations in humans 
upon CLA supplementation, either as a mix of isomers or as purified t10,c12 
CLA(35)(37)(72).  It would seem that, on this brief evaluation, CLA's organismal 
physiological effects are not the result of alterations in leptin secretion, potentially 
indicating that changes in body composition related to CLA supplementation are not 
necessarily the result of altered energy homeostatic signaling.
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To examine other physiologic changes related to CLA supplementation, adipokine-
related insulin sensitivity was investigated.  Insulin resistance can be the result of a 
number of metabolic and hormonal changes besides the classic view of glucose and 
insulin concentrations.  One such related hormonal change is from the adipokine 
adiponectin.  Unlike leptin and other adipokines, circulating adiponectin 
concentrations, are inversely proportional to body fat mass(73).  With the 
observation that adiponectin improves hepatic insulin sensitivity(73), it may be an 
important hormone to study in regard to CLA supplementation.  
An animal model of male mice showed insulin resistance upon feeding with 1.5% 
energy as mixed CLA isomers.  The insulin resistance was purportedly caused by 
adiponectin depletion, and reversed upon removal of CLA from the diet. 
Administering rosiglitazone, a PPARγ agonist, to upregulate adiponectin production 
prevented depletion of adipose tissue and also prevented insulin resistance(44). 
However, one study in diabetic rats demonstrated improved insulin sensitivity with a 
concomitant increase in circulating adiponectin, which may be one explanation for 
the differences between mice and rats in insulin sensitivity related to CLA(45).  In 
fact, another study where insulin sensitivity was improved in rats supplemented with 
CLA showed that both common CLA isomers, separately or together, increased the 
expression of adiponectin receptors R1 and R2 in the liver(74).  These data strongly 
suggest a role of adiponectin and PPARγ as a mechanism of action for the 
physiologic effects of CLA.  The question then becomes whether humans are more 
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like rats, with CLA improving adiponectin and insulin sensitivity, or more like mice, 
with CLA decreasing both adiponectin and glucose tolerance, which only rigorous 
research may answer.  
With a body of controversial evidence suggesting or refuting the notion that CLA can 
increase or decrease adiposity, only two studies to date reported adiponectin 
concentrations related to CLA supplementation in humans(75)(76).  After 6 months 
of CLA supplementation of 3.4 g/d of a 50:50 mixture of the two most prominent 
isomers of CLA, Syvertsen and colleagues measured no alterations in circulating 
adiponectin concentrations.  Using the euglycemic hyperinsulinemic clamp method 
of determining insulin resistance, which is considered the gold standard, the 
researchers found no significant differences in insulin sensitivity.  They also noted no 
differences in BMI or body fat percentage(75).  In another study, Risérus and 
colleagues compared a mix of CLA isomers or the t10,c12 isomer alone against a 
control, and also found no differences in adiponectin concentrations, though a 
decrease in insulin sensitivity was observed(76).  Because adiponectin 
concentrations are correlated with body composition, the demonstrated lack of 
change in concentrations presented in these two studies does not preclude 
adiponectin as important in studies where body compositional changes are 
observed, but so far the research does not seem to strongly implicate adiponectin as 
an important mechanism by which CLA acts.
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Circulating lipids are primarily cleared by uptake of lipoprotein particles by the liver 
or the hydrolysis of TAG in the blood.  With the upregulation of PPARγ, a 
concomitant increase in LPL has been noted, which would result in clearance of 
circulating lipids into the adipocyte(69).  Downregulation of LPL, then, would aid in 
the adipocyte delipidation shown in at least one model(71).  A different PPAR, 
PPARα, may also be implicated in circulating cholesterol concentrations, which are 
affected by addition of cholesterol to, and clearance from, the blood.  Cell models 
using human hepatoma (HepG2) cells demonstrated an upregulation of the LDL 
receptor in response to treatment with t10,c12 CLA, which could result in improved 
LDL clearing, and would therefore decrease circulating cholesterol and TAG as 
shown in some models(77).
Eicosanoids, which are other agonists of PPARγ, are synthesized from the two 
essential fatty acids in humans: linoleic and linolenic acids.  Thus, CLA's effects on 
essential fatty acid metabolism could be a concern.  However, at a supplementation 
of 1.2 g/d of either c9,t11 or t10,c12 CLA for 7d, Turpeinen and colleagues did not 
observe any alterations in linoleic or linolenic acid metabolism, indicating that CLA 
may not interfere with the metabolism of the essential fatty acids(78).
Still yet another mechanistic concern is that there is a growing body of evidence to 
suggest that CLA may have sex-specific effects, as indicated before in the review of 
insulin resistance research.  One potential explanation for these differences could be 
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CLA's effects on estrogen.  In particular, cell culture work has indicated that CLA 
inhibits estrogen response elements and partially regulates estrogen activity through 
estrogen receptor dephosphorylation(79).  This reinforces the notion that CLA may 
effect males and females in different ways(41).
Conclusions
CLA supplementation in humans has resulted in inconsistent and often antagonistic 
conclusions from one experiment to the next.  While there are trends for alterations 
in body fat mass, adiposity, circulating cholesterol concentrations, insulin resistance, 
and other markers of health, no definitive comments can be made on CLA 
supplementation.  One theory for the variation in responses to CLA supplementation 
is the matrix in which the supplement is given.  Some studies reviewed here 
incorporated CLAs by artificially adding them to foods and pills, in free fatty acid form 
or in TAG form; other studies have severely altered the eating patterns of cattle to 
produce beef and dairy products rich in CLA.  Furthermore, there is clear evidence 
for isomer-specific differences in human response, as well as differences in sex, 
body composition, and insulin sensitivity at the onset of supplementation.
A natural supplement has yet to be tested.  As reviewed, ruminant animals are 
capable of producing CLA from certain dietary lipids, but as the practice of grain-
feeding cattle has increased, the CLA content has generally decreased.  Some 
studies have tried to alter the dietary rations of cattle in a manner to promote CLA 
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production and publish under the notion that this is natural incorporation; however, 
organizations such as the American Grassfed Association do not consider feeding 
cattle fish oils and flax seed natural(80).  Furthermore, these oils may result in 
rumen dysfunction(12).  With this in mind, we have proceeded to conduct a research 
study on humans in which the CLA supplement is in a natural food matrix, produced 
by pasturing cattle, with the placebo products from grain-fed cattle.  The following 
chapter is the description of the study in a journal article format.
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Chapter III:  Presentation of Research
Abstract
Background:  Conjugated linoleic acid (CLA) purportedly alters body composition, 
glucose tolerance, hepatic function, lipoprotein distributions, and other markers of 
health.  However, results of research are often inconclusive or contradictory, and 
presently no studies have investigated the effects of natural incorporation of CLA 
from pasture-fed cattle.
Objective:  The present study investigated the effects of two diets high in beef and 
dairy products, one diet comprised of products from a pasture-fed system that were 
naturally enriched with CLA and one diet comprised of commercial products of grain-
fed origin that were naturally deficient in CLA, on insulin resistance, body 
composition, circulating lipids, and other selected disease risk factors.
Design:  Eighteen healthy women age 20-39 y consumed one of two diets for 56 d. 
Balanced, nutritionally complete diets comprised of 31% energy from lipid, 13% 
protein, and 54% carbohydrates were administered with the primary difference being 
CLA content (CLA group: 1.17 g/d; Control group: 0.35 g/d).
Results:  The CLA diet did not result in any differences in insulin sensitivity, body 
composition, circulating blood lipids, nor other measured disease risk factors as 
compared with the Control diet.
Conclusion:  A diet naturally enriched with a 3.5 fold increase in CLA by 
incorporation of beef and dairy products from pasture-fed cattle did not result in 
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measurable improvements in selected measures of health in premenopausal women 
as compared with a similar diet with beef and dairy products from grain-fed cattle.
Introduction
Various isomers of conjugated octadecadienoic acid, also known as conjugated 
linoleic acid (CLA), have been reported to both improve and impair markers of health 
in humans.  Experimental results have reported improving(49)(57) and impairing(58)
(47) circulating lipids, increasing(37)(41) and decreasing(48) insulin sensitivity, 
depleting(31) or not altering fat mass(35), and increasing(68) or not changing(67) 
indicators of liver necrosis.  Still other studies have shown no effects in some or all 
measured risk factors(18)(37)(60).
Some of the variation in results may be explained by the variation in the studies 
themselves.  Different experiments on male or female subjects caused differing 
results in terms of insulin resistance: CLA appears to improve insulin sensitivity in 
women(37)(41), whereas men remain unchanged(18)(46) or worsen(48).  Body 
composition prior to CLA supplementation also may play a factor: experiments have 
resulted in improved body composition in non-obese participants(31)(32) but no 
change in obese subjects(31)(34).  Still other research indicates differences in CLA 
isomer composition as a source of varying results, with the t10,c12 isomer showing 
some effects and the c9,t11 isomer showing others(47).
Most published studies have used CLA supplementation in the form of commercially 
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available pills provided to free living adults.  However, the discovery of the potential 
health benefits of CLA are generally attributed to Pariza and colleagues who showed 
CLA from pan-fried hamburgers had anti-mutagenic properties(21).  Thus, we have 
found it appropriate to return to the roots of CLA research: the natural incorporation 
of CLA in food.
CLAs are most commonly found in ruminant products because of the partial 
biohydrogenation that occurs in the rumen(5) and the subsequent desaturation of 
trans-vaccenic acid to c9,t11-CLA(14).  Feeding patterns and practices of ruminant 
livestock are known to alter the fatty acid composition (including CLA content) of 
products derived from these animals.  In particular, bovine consuming quickly 
growing pasture tend to produce the highest natural concentrations of CLA 
commonly available to Americans, with CLA content increasing with longer grazing 
periods(16).  Supplementing ruminants' diets with oils has a more marked effect on 
CLA concentrations in bovine-derived products, such as sunflower oil resulting in a 
three fold increase in CLA(2), linseed enrichment causing a two fold increase(2), and 
a 2:1 mix of sunflower oil and fish oil resulting in about a ten fold increase(18). 
Whether the endogenous enrichment is the result of oils or pasture, the increase in 
CLA is predominantly in the c9,t11 isomer(18)(16)(2). 
To the best of our knowledge, only one study to date has investigated the effects of 
feeding dairy products endogenously enriched in CLA to humans(18).  However, the 
enrichment was through supplementing dairy cattle with fish and sunflower oils, 
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which are unnatural to the cattle's diet.  Whether or not oil supplementation 
constitutes natural enrichment with CLA is, therefore, debatable, especially among 
farmers who believe in strict pasture feeding.  In the spirit of determining the effects 
of CLA naturally incorporated into foods, our objective is to compare the effects of 
beef and dairy products from pasture-fed cattle, which are naturally enriched with 
CLA, against beef and dairy products from grain-fed cattle, which are naturally 
deficient in CLA, in terms of insulin resistance, body composition, circulating blood 
lipids, and other disease risk factors in healthy female subjects.
Materials and Methods
Human participants
Research was approved by the Iowa State University Institutional Review Board, 
and all women screened signed an informed consent document.
Women between the ages of 20 and 40, with a body mass index (BMI) between 19 
and 30 (normal and overweight), not pregnant or nursing, non-smoking, non- to 
moderate-drinkers, and who considered themselves to be in good health were 
invited to be screened for participation.  Screening included determination of height, 
weight, and BMI, completion of a medical history questionnaire, and a fasting blood 
sample analyzed by Laboratory Corporation of America (LabCorp; Omaha, NE) for 
serum triacylglycerols (TAG), total cholesterol (TC), and high-density lipoprotein 
cholesterol (HDL).  Over 7000 women within the age limits were contacted, of which 
56 women thought they fit the criteria and agreed to be screened, and 19 women fit 
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the previously stated criteria, as well as having serum cholesterol concentrations 
near or above the median for their age as determined by The Third National Health 
and Nutrition Examination Survey (NHANES III).  One participant discontinued 
participation during the first weekend as a result of an injury unrelated to the study. 
The characteristics at screening of the women who completed participation in the 
study are summarized in Table 1.
Experimental procedures
Diets were formulated using Nutritionist Pro (version 2.3; First DataBank, Inc.; San 
Bruno, CA) by a registered dietitian.  Diets were formulated to average 2000 kcal/d 
with 35% of calories coming from lipid, 15% from protein, and 50% from 
carbohydrate, which approximates the average composition consumed by females 
age 20-40 y in the United States(81).
Beef with elevated concentrations of CLA was obtained by selecting from a group of 
organic, pasture-fed steers harvested after a period of rapid pasture growth.  The 
control ground beef was obtained from a feedlot, grain-fed steer.  Beef was ground 
into 85% lean ground beef.
Dairy products high in CLA were obtained from organic, pasture-fed dairy cattle.  Ice 
cream was obtained from Pastureland Creamery (Woodward, IA), cheese was 
obtained from Farmers All Natural Creamery (Wellman, IA), and butter was 
generously donated by PastureLand Cooperative (Minneapolis, MN).  Commercial 
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products from grain-fed cattle were analyzed to find a control product similar to the 
treatment products in macronutrient composition and energy density.  Haagen-Dazs 
vanilla ice cream (Oakland, CA), FastCo cheddar cheese (Boone, IA), and Land-O-
Lakes butter (Saint Paul, MN) were chosen for the Control products.
All meals were prepared in Iowa State University’s Human Metabolic Unit (HMU). 
Participants consumed 3 meals/d during weekdays in the HMU; lunch on Sunday 
was also served in the HMU.  All of Saturday's meals, as well as breakfast and 
dinner on Sundays, were prepared in the HMU and sent home with reheating 
instructions.  Participants were asked to consume no foods or beverages other than 
those provided, with the exceptions of water, tea, coffee, and no-calorie soft drinks 
sweetened with Splenda® (McNeil Nutritionals; Ft. Washington, PA) for the duration 
of the 56 d intervention.  Splenda was included as a manner in which to increase 
participant compliance, and was determined to be fairly inert in terms of measured 
outcomes for the present study, as outlined in Appendix A.
Blood sample collection
Participants were asked to fast for at least 10 h prior to day 0 and again before day 
56.  An intravenous catheter (IV) was inserted into the arm of each participant by 
registered nurses.  Fasting serum samples were collected with BD Vacutainer 
Serum Separator tubes for analysis by LabCorp, and fasting plasma samples were 
collected in BD Vacutainer EDTA tubes (BD; Franklin Lakes, NJ).  An oral glucose 
tolerance test (OGTT) was conducted by administering a 75 g glucose drink (SUN-
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DEX No. TG30010P, Fisher Scientific; Pittsburgh, PA) that was to be consumed 
within five minutes of being administered.  Blood was again drawn via IV and 
transferred to EDTA treated tubes at 30, 60, 90, 120, 150, and 180 minutes after 
completion of the glucose drink.
Serum was allowed to coagulate at room temperature for 20-40 minutes, per 
LabCorp's instructions.  EDTA tubes were kept on ice until centrifugation.  Blood 
samples were centrifuged at 3000 x g for 15 minutes at 4ºC.  An aliquot of plasma 
was treated with 50 µl of 5500 KIU/mL aprotinin (Sigma; St. Louis, MO) and stored in 
a glass tube for analysis of glucagon.  All other plasma samples were aliquoted into 
plastic microfuge tubes and stored at -20ºC until analyzed.
Lipoproteins were isolated from 3 mL of fasting plasma sample by a sequential 
flotation ultracentrifugation method modeled after Havel et al(82).  Briefly, plasma 
was transferred to a 4 mL polycarbonate tube and layered with a solution equal in 
density to the infranatant for a total volume of 3.9 mL.  The sample was centrifuged 
at 109,000 x g for 20 hours at 18ºC in a Beckman Ti 50.4 rotor in a L8-M 
ultracentrifuge (Beckman; Palo Alto, CA); 1.8 mL of supernatant were transferred to 
a 2 mL Corning Cryogenic Vial (Corning, Inc; Lowell, MA).  The infranatant was then 
adjusted to the next density by addition of 1.5 mL of a more dense solution, layered 
with 0.3 mL of the same density as was adjusted to, and the centrifugation 
procedure was repeated.  The obtained fractions were of the following densities in g/
mL: very low-density lipoproteins (VLDL) < 1.006 < intermediate-density liporoteins 
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(IDL) < 1.019 < low-density lipoproteins (LDL) < 1.063 < high-density lipoprotein 
subfraction II (HDLII) < 1.125 < high-density lipoprotein subfraction III (HDLIII) < 1.21. 
Analysis of selected markers of health
Concentrations of TC were determined from each lipoprotein fraction by colorimetric 
assay (Kit C7510, Pointe Scientific; Canton, MI).  Glucose was colorimetrically 
quantified from the OGTT samples (Kit G7521, Pointe Scientific).  Insulin and 
glucagon were measured from the OGTT samples by radioimmunoassay (HI-11K 
and GL-32K, respectively, Linco Research; St. Charles, MO), as were fasting 
concentrations of adiponectin (HADP-61HK, Linco Research).
LabCorp results were analyzed for differences in aspartate aminotransferase (AST), 
alanine aminotransferase (ALT), and TAG, as well as used as a quality control for 
the in-lab analysis of lipoprotein fractions.
Body composition was determined using a Hologic Delphi W dual-energy X-ray 
absorptometer (DXA) (Hologic Inc.; Bedford, MA).
Diet analysis
An extra set of meals was collected daily for each treatment including all provided 
foods and liquids.  Daily total provided intake was determined gravimetrically. 
Samples were stored at 4ºC until homogenized using a Waring industrial blender 
with a cooling coil (Waring Commercial 4L Laboratory Blender, 4L 2610T coil; New 
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Hartford, CT) set to 4ºC by a cryogenic cooler (Caron Model 2050; Marietta, OH). 
Homogenate was frozen at -20ºC until analyzed.
Daily dry matter intake was determined by lyophilizing 5 replicates of 5 g aliquots of 
daily intake homogenates.  Protein was approximated using a micro-Kjeldahl 
procedure to determine nitrogen content(83).  Briefly, 60 ± 3 mg of the dry matter 
samples were added to Kjeldahl tubes in duplicate; a Kjeltab (Thompson and 
Capper Ltd; UK) and sulfuric acid were added to each tube.  Samples were digested 
for 4 h, and titrated to determine total nitrogen.  Protein was approximated using a 
factor of 6.25 times the nitrogen content.
Total lipids were extracted from 2 g samples of daily homogenates in triplicate by a 
modified Folch procedure, using 2:1 chloroform:methanol (v:v)(84) under nitrogen to 
prevent oxidation; lipid content was then determined gravimetrically.
Fatty acid methyl esters (FAME) were prepared from lipid extracts using sodium 
methoxide as a methanolic base(85). Samples were analyzed on a Varian 3350 gas 
chromatograph with a flame ionizing detector equipped with a Varian 8200CX 
autosampler (Varian; Palo Alto, CA) and a Supelco 2560 fused silica capillary 
column (100 m x 0.25 mm x 0.2 μm film thickness, Sigma) under the following 
column conditions: initial column temperature was set to 70ºC and held for 2 min; 
increased to 165ºC at 19ºC/min and held for 20 min; increased to 192ºC at 
0.6ºC/min and immediately increased to 230ºC at 50ºC/min and held for 15 min for a 
38
total run time of 87.76 min.  FAMEs were identified by retention times compared with 
purified lipid standards (NuCheck; Elysian, MN).
Trimethylsilyl derivatives of dietary sterols were prepared from the non-saponifiable 
fraction of the total lipid extract.  Briefly, 5α-cholestane was added as an internal 
standard and the lipid extract was saponified by addition of 11% w/v potassium 
hydroxide in a 55% v/v ethanol/deionized water solution.  The non-saponifiable 
fraction was isolated and derivatized with N,O-Bis(trimethylsilyl)trifluoroacetamide 
with 1% trimethylchlorosilane (Thermo Scientific Pierce; Rockford, IL).  Sterol 
derivatives were analyzed on the gas chromatograph described above equipped 
with a 30m Supelco column with an initial column temperature of 150˚C increased to 
200˚C for 20 min followed by an increase to 250˚C for 30 min.  Standards were 
prepared and analyzed the same way, and cholesterol derivatives and 5α-
cholestane in the samples were identified by retention times compared with 
derivatized standards.
Statistical analysis
All statistics were computed using SAS (version 9.1, SAS Institute Inc.; Cary, NC). 
Screening cholesterol concentrations were used to pair individuals with similar 
cholesterol, randomize the pairs to treatments, and pairing removed for all further 
analyses.  Change scores were calculated by subtracting the day 0 values from the 
day 56 values, where appropriate.  Change scores and baseline values were 
compared between treatments; change scores were also analyzed with the student's 
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t-test against zero to determine if values significantly changed from the beginning to 
the end of the study.  Timecourse data generated for plasma glucose, insulin, and 
glucagon concentrations from the OGTT were analyzed for differences in fasting 
values, within treatment changes, and differences between treatment change scores 
at each timepoint.  Curves were compared using the GLM procedure with repeated 
measures, or as change scores for the areas under the curves (AUCs).  Statistical 
significance was considered p < 0.05.
Results
Diet compositions
The compositions of the analyzed experimental diets were reasonably close to the 
target composition (Table 2).  Though the experimental and target compositions 
differed slightly in each macronutrient, the values obtained indicate a fairly similar 
dietary composition between the administered Control and CLA diets that resulted in 
no significant differences in calculated intake of total energy, carbohydrate, or protein 
(all p > 0.1), and a small (~2%), though statistically significant, difference in lipid 
percentage.  Cholesterol intake was similar between the two diets.
Fatty acid profiles of the diets were similar in saturated fatty acid (SFA), 
monounsaturated fatty acid (MUFA), and polyunsaturated fatty acid (PUFA) content, 
but with a significant difference in total CLA content and in specific isomers of CLA 
(Table 3).  In the CLA diet, 1.17% of the identified FAME were CLA isomers, 
predominantly the c9,t11 isomer; the control diet contained 0.35% of the identified 
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FAME as CLA, with only the c9,t11 isomer being detected.
Blood lipids
Changes in cholesterol concentrations in individual lipoprotein fractions, as well as 
the sum of the cholesterol fractions, were analyzed (Figure 1).  No differences in 
cholesterol concentrations were seen between treatments at day 0 in any fraction, 
nor in TC.  After dietary intervention, the IDL fraction decreased significantly within 
treatment from day 0 in both the Control and CLA groups (-3.1 and -2.2 mg/dL, 
respectively), as did the HDLIII fraction (-8.3 and -7.8 mg/dL, respectively); the other 
fractions did not change significantly from day 0.  Though the HDLIII fraction 
changed from day 0 to day 56 within the treatments, total HDL concentrations (HDLII 
+ HDLIII) did not.  No significant differences were observed in change scores 
between treatments in any fraction or in TC.
Concentrations of TAG in plasma were consistent throughout the study (Figure 2). 
No differences between total TAG concentrations between the two treatments were 
observed at day 0, nor did TAG concentrations change within treatments from day 0. 
Furthermore, changes in TAG concentrations from the beginning of the study to 
completion did not differ between treatments.
Body composition
Total body DXA scans were divided into left and right arms and legs, trunk and head. 
The analyses of the trunk values are shown in Figure 3.  Trunk compositions did not 
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differ significantly at day 0 between treatments, nor did the change scores differ 
between the two treatments.  However, within each treatment there was a significant 
decrease in trunk fat mass (Control: -1.0 kg; CLA: -0.9 kg), with no significant 
change in trunk lean mass.  Both groups also showed a within treatment decrease in 
total trunk mass (Control: -1.0 kg; CLA: -1.2 kg).  The changes in trunk fat and total 
mass resulted in a statistically significant 2% decrease in trunk fat mass percentage 
within each treatment, but this change did not differ between treatments.
In a separate analysis, the values obtained from the left and right legs and arms, as 
well as the trunk, were summed and analyzed as subtotal body composition values 
(Figure 4).  Similar to the trunk composition, no differences between treatment 
groups before intervention were noted, nor were there any differences in the change 
scores between treatments.  Also similar to the trunk composition, the subtotal fat 
mass decreased within each treatment from baseline (Control -1.8 kg; CLA -1.9 kg), 
there were no within treatment changes in subtotal lean mass, and there was a 
within treatment decrease in subtotal total mass (Control: -2.3 kg; CLA -1.8 kg).  A 
statistically significant 2% decrease in fat mass was observed in the subtotal 
composition within each treatment, which did not differ significantly between 
treatments.
OGTT
Qualitatively, mean glucose concentrations across timepoints in both groups 
appeared to converge to much more similar curves after intervention as compared 
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with before, though no significant differences were observed between groups in the 
pre-treatment glucose timecourse data (Figure 5).  Only the 30 min timepoint 
differed significantly within treatment from the beginning of the study to the end.  No 
differences were observed between the change scores of the two treatment groups 
at each timepoint, nor did the curves differ significantly from pre- to post-treatment. 
Analysis of the AUCs revealed that the Control subjects averaged a significant 
increase of 2091 min*mg/dL, which is a 15% increase in the glucose AUC from the 
beginning of the study to the end; no significant change was observed within the 
CLA group, nor did the changes in glucose AUC differ between groups.
Glucagon and insulin curves (Figures 6 and 7) both showed no differences between 
groups on day 0 of the study.  Neither curve changed significantly from day 0 within 
treatment, and the within treatment changes in the curves did not differ significantly 
between the treatments.  Concomitantly, no changes were seen between or within 
groups when AUCs were calculated for the glucagon and insulin time course data.
Fasting adiponectin concentrations did not differ significantly at day 0 (Figure 8), nor 
did they differ within or between treatments during the course of the experiment.
Liver necrosis
Fasting AST and ALT activities are shown in Figures 9 and 10.  Neither AST nor ALT 
activities differed between treatment groups at baseline.  Activities did not change 
during the course of the study between or within groups.
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Discussion and Conclusions
The focus of the present investigation was the comparison of the effects of naturally 
occurring CLA in beef and dairy products from pasture-fed cattle versus beef and 
dairy products naturally deficient in CLA from grain-fed cattle.  An increase in CLA, 
however, cannot occur without either increasing total lipid intake or decreasing 
another fatty acid constituent of the diet.  The fatty acid compositions of the 
administered diets reported in Table 3 indicate that the content of some fatty acids 
other than CLA differed significantly between the two diets.  In particular, the lipid 
percentages of individual identified saturated and monounsaturated odd chain FAME 
were higher in the CLA diet than the Control diet.  Little research has been done on 
odd chain fatty acids with regard to health, with relevant literature being dominated 
by disorders in propionate metabolism.  Furthermore, the ratio of identified ω3:ω6 
FAME was significantly different (1:9.4 Control; 1:5.8 CLA); particularly, arachidonic 
acid (C20:4-n6), a precursor of inflammatory prostaglandins and a constituent of 
endocannabinoids, was lower in the CLA diet and α-linolenic acid (C18:3-n3), an 
essential fatty acid related to decreased cardiovascular disease, was higher in the 
CLA diet.  It is important to note, though, that the difference in CLA content between 
the two diets was one of the largest differences observed in fatty acid content, with 
only the magnitude difference of palmitate and oleate being larger; furthermore, the 
~3.5 fold increase in CLA content between the Control and CLA diets was the largest 
relative change of all measured fatty acids.  Therefore, even though confounding 
fatty acid differences are evident, CLA content remains one of the most striking 
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differences between the two diets.
The macronutrient compositions of the experimental diets were reasonably close to 
the target macronutrient composition (Table 2).  The deviations from the target 
composition seen in the administered diets can be largely explained by experimental 
assumptions.  Dry matter intake was divided into lipid, protein, and carbohydrate, of 
which only lipid and protein were measured.  For the sake of approximation, all 
additional dry matter was assumed to be digestible carbohydrate, and was given the 
energy value of 4 kcal/g.  Thus, carbohydrate and total energy intakes were lower, 
while protein and lipid intakes were higher, than the analyzed approximations. 
However, most of the carbohydrates in the diets came from foods common to the 
two diets; also, consistency in the measurements indicate that the assumptions are 
viable for comparison purposes within this experiment.
A number of factors may contribute to the variety of responses seen in human 
research on CLAs.  Cell culture work related to breast cancer has shown that CLA 
inhibits estrogen response elements and partially regulates estrogen activity through 
receptor dephosphorylation(79), reinforcing the concept of gender differences in 
response to CLA supplementation.  Where possible, the present study will be 
compared to studies on women.  However, much CLA research has been conducted 
on mixed groups of men and women without separating out the gender effects, and 
many studies conducted on women focus on post-menopausal or lactating women, 
leaving few studies that have examined the effects of CLA supplementation on 
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healthy young females who are not pregnant or lactating.
The correlation of lipoprotein distribution with cardiovascular diseases has been well 
established(51).  In particular, the ApoB containing lipoproteins, VLDL, IDL, and LDL, 
have been positively correlated with atherosclerosis, whereas HDL is negatively 
correlated with atherosclerosis, and in particular the HDLII fraction(53).  Thus, we 
measured five lipoprotein fractions: VLDL, IDL, LDL, HDLII, and HDLIII.  While no 
differences were seen between treatment groups, both groups on the study showed 
a decrease in IDL, which has been strongly implicated in coronary artery 
disease(52).  Though a decrease was seen in the HDLIII fraction, no differences 
were seen in total HDL or in the HDLII fraction in both groups.  It appears, then, that 
both groups exclusively may have a marginally decreased risk for cardiovascular 
diseases.  In other studies of CLA supplementation on women, no differences were 
seen in TC, LDL or HDL between CLA and placebo treatments(37)(41)(61), in 
agreement with the results of the present study.
Circulating concentrations of TAG did not change in the present study, which agrees 
with several studies conducted in women with mixed CLA isomers from 2.1 to 3.6 g/
d and from 6 weeks to 12 weeks in duration(37)(41)(61).  Endogenous incorporation 
of CLA in dairy products supplemented to men did not result in differences in TAG 
concentrations either(18), indicating a fair amount of consistency in the literature.
The lack of effect of CLA supplementation on body composition shown in the present 
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study complements a similar absence of effect reported in a well controlled, 
isocaloric study on healthy females in a metabolic ward(86), as well as in a study of 
free living adult women(61).  The absence of an effect is in stark contrast with other 
studies in which mixed isomers of CLA were supplemented at about 3.5 g/d to free-
living women eating ad-libitum diets(37), nor does the present study support the 
conclusion that CLA decreases fat mass in a body-region specific manner(40). 
However, the observed 2% decrease in body fat mass in the CLA group in the 
present study fits the trend line demonstrated in Gaullier and colleagues' one year 
supplementation study(87), though the 2% decrease in body fat mass in the Control 
group does not.  While one study reported differences in as little as 6 weeks(37), 
other studies have shown differences in 6 months(40) to 1 year(87), indicating the 
potential for CLA to have more of a chronic, rather than acute, effect on body 
composition, which is supported by a meta-analysis indicating a decrease in fat 
mass of 24 g/week for each gram of CLA supplemented(42).  Such a decrease in fat 
mass would be too small to detect with significance in the present study.
Several reports have indicated that CLA supplementation results in improved insulin 
sensitivity or glucose tolerance in females(37)(41), without the corresponding effects 
in males(46).  The present study does not support this trend, with no changes in 
glucose or insulin concentrations between the Control and CLA groups.  Also, 
adiponectin, which increases hepatic insulin sensitivity(73), did not change between 
groups either.  These results confirm other research that reports no alterations in 
adiponectin concentrations with(76) or without(88) concomitant changes in insulin 
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sensitivity.  The c9,t11-CLA isomer, which was the most prominent isomer in the 
present study, upregulates peroxisome proliferator-activated receptor gamma 
(PPARγ), for which adiponectin is a target gene(70), so adiponectin concentrations 
would be expected to increase; in addition, adiponectin is inversely correlated with 
body fat mass(73), so the decrease in body fat mass should have resulted in a within 
treatment increase in circulating adiponectin concentrations.  However, no change in 
adiponectin concentrations were observed, which coincides with no change in insulin 
sensitivity.
A report of CLA causing hepatomegaly in animal models(65) led to the desire to 
measure biomarkers of liver health, in particular AST and ALT.  No changes in liver 
enzyme activity in the blood is an indication that liver integrity did not change during 
the course of the study within or between treatments, which agrees with the findings 
of other research(68)(67)(61).
While the results from the present study coincide with some other reports, the 
discrepancies with other studies can be explained in a number of ways: the present 
study used endogenously incorporated CLA, which is primarily comprised of the 
c9,t11-isomer, whereas many other studies use mixed isomer, commercially 
prepared supplements; the present study was an energy-controlled study, in which 
all foods were provided, whereas most other studies supply supplements to free 
living participants; the present study was conducted on healthy, non-pregnant, pre-
menopausal, adult female participants, whereas many studies are conducted on 
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both sexes, males, or pregnant, lactating, or post-menopausal women; the present 
study was conducted over 8 weeks, whereas other studies have been shorter, or as 
long as two years.  The fact that sex, isomer, source of supplementation, energy 
intake, and duration of supplementation, among other factors, all may influence the 
effects of CLA on biomarkers of health indicates the need for more research. 
Therefore, we can only conclude that consuming diets for 8 weeks that were high in 
beef and dairy products naturally enriched with CLA from pasture-fed cattle did not 
result in improvements in selected markers of health in healthy, pre-menopausal 
women when compared with similar foods from grain-fed cattle; extrapolation to 
other populations, supplementation methods, or isomer contents would not be 
prudent.
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Figure 1.  Cholesterol concentrations in five lipoprotein fractions
Lipoprotein fractions were classified by density and separated by sequential flotation 
from plasma samples taken on days 0 and 56 from the Control and CLA treatment 
groups.  Cholesterol concentrations were quantified from each lipoprotein fraction; 
bars represent means.  The fractions have the following densities: VLDL <1.006 < 
IDL < 1.019 LDL < 1.063 < HDLII < 1.125 < HDLIII <1.21.  No between treatment 
differences were noted.  The significance of within treatment changes from day 0 to 
day 56 are denoted by: + p=0.05; * p<0.05; ** p<0.01.
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Figure 2.  Total circulating TAG concentrations
Serum TAG concentrations were quantified on day 0 and day 56 for each treatment 
(Mean±SEM).  No significant differences were noted between or within treatments at 
p<0.05.
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Figure 3.  DXA results for trunk compositions
Trunk lean, fat, and total masses for Control and CLA treatment groups at day 0 and 
day 56 were quantified by DXA (Mean±SEM).  No significant differences between 
treatments were observed.  Both treatment groups experienced a significant within 
treatment decrease in body fat (Control: -1.0 kg; CLA: -0.9 kg) and total (Control: 
-1.0 kg; CLA: -1.2 kg) masses.  Within treatment differences are denoted by * 
(p<0.05).
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Figure 4.  DXA results for subtotal compositions
Subtotal (full body excluding the head) lean, fat, and total masses for Control and 
CLA treatment groups at day 0 and day 56 were quantified by DXA (Mean±SEM). 
No significant differences between treatments were observed.  Both treatment 
groups experienced a within treatment significant decrease in body fat (Control: -1.8 
kg; CLA: -1.9 kg) and total (Control: -2.3 kg; CLA: -1.8 kg) masses.  Within treatment 
differences are denoted by * (p<0.05).
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Figure 5.  Glucose concentrations during OGTT
Glucose concentrations were measured by colorimetric enzymatic assay from 
samples obtained before administering a 75g glucose drink (time=0) and every half 
hour after the drink was consumed for 180 min on days 0 and 56 for both treatment 
groups (Mean±SEM).  Points are connected by a smoothed spline.  No differences 
were seen between treatments.  The AUC of the Control glucose concentration 
curve increased significantly from day 0 to day 56 by approximately 15%.  Significant 
within treatment timepoint changes from day 0 to 56 were only observed at 30 min (* 
designates p<0.05).
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Figure 6.  Glucagon concentrations during OGTT
Glucagon concentrations were measured by radioimmunoassay from samples 
obtained before administering a 75g glucose drink (time=0) and every half hour after 
the drink was consumed for 180 min on days 0 and 56 for both treatment groups 
(Mean±SEM).  Points are connected by a smoothed spline.  No significant 
differences were observed between or within treatments at p<0.05.
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Figure 7.  Insulin concentrations during OGTT
Insulin concentrations were measured by radioimmunoassay from samples obtained 
before administering a 75g glucose drink (time=0) and every half hour after the drink 
was consumed for 180 min on days 0 and 56 for both treatment groups 
(Mean±SEM).  Points are connected by a smoothed spline.  No significant 
differences were observed between or within treatments at p<0.05.
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Figure 8.  Fasting adiponectin concentrations
Fasting plasma adiponectin concentrations were quantified by radioimmunoassay on 
days 0 and 56 in Control and CLA treatment subjects (Mean±SEM).  No significant 
differences were observed between or within treatments at a significance of p<0.05.
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Figure 9.  AST activities
Serum AST activities were quantified as a surrogate marker of liver integrity on days 
0 and 56 from the Control and CLA treatment groups (Mean±SEM).  No significant 
differences were observed within or between groups at a significance of p<0.05.
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Figure 10.  ALT activities
Serum ALT activities were quantified as a surrogate marker of liver integrity on days 
0 and 56 from the Control and CLA treatment groups (Mean±SEM).  No significant 
differences were observed within or between groups at a significance of p<0.05.
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Table 1.  Screening characteristics of selected female participants who agreed 
to participate
Characteristic Mean± SD1
Total Cholesterol (mg/dL) 185.4± 17.8
HDL-C (mg/dL) 70.3± 14.8
LDL-C (mg/dL) 94.5± 16.1
TAG (mg/dL) 102.6± 67.5
BMI (kg/m2) 24.3± 5.1
Age (y) 24.1± 4.7
1n=18
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Table 2.  Compositions of experimental diets
Target CLA1 Control1 p-value2
Energy (kcal/d) 2000 2129 ± 34 2203 ± 30 0.1043
Lipid (% of energy) 35 30.5 ± 0.6 32.5 ± 0.6 0.0310
Protein (% of energy) 15 13.0 ± 0.3 12.6 ± 0.2 0.3581
Carbohydrate (% of energy) 50 56.5 ± 0.7 54.9 ± 0.7 0.1133
Cholesterol (mg/d) 300 270 ± 23 303 ± 24 0.3302
1 x ± SEM         2 CLA vs Control
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Table 3.  Fatty acid compositions of experimental diets
Category Fatty Acid CLA1 Control1 p-value2
SFA Total 52.97 ± 0.66 53.56 ± 0.60 0.5085
4:0 0.51 ± 0.04 0.47 ± 0.04 0.5316
6:0 0.93 ± 0.05 0.88 ± 0.04 0.4260
8:0 0.68 ± 0.03 0.65 ± 0.03 0.4267
10:0 1.63 ± 0.04 1.58 ± 0.04 0.4273
11:0 0.19 ± 0.00 0.16 ± 0.01 0.0003
12:0 1.89 ± 0.04 1.87 ± 0.04 0.7410
13:0 0.10 ± 0.00 0.10 ± 0.00 0.9258
14:0 7.77 ± 0.18 7.34 ± 0.14 0.0687
15:0 1.03 ± 0.03 0.74 ± 0.01 <0.0001
16:0 27.10 ± 0.34 28.54 ± 0.30 0.0022
17:0 0.65 ± 0.01 0.59 ± 0.01 0.0001
18:0 10.28 ± 0.09 10.46 ± 0.11 0.1825
20:0 0.17 ± 0.00 0.15 ± 0.01 0.0025
24:0 0.05 ± 0.01 0.02 ± 0.01 0.0152
MUFA Total 32.17 ± 0.21 32.77 ± 0.22 0.0549
13:1 0.11 ± 0.01 0.05 ± 0.01 <0.0001
14:1 1.45 ± 0.03 1.14 ± 0.02 <0.0001
15:1 0.21 ± 0.02 0.14 ± 0.01 0.0008
16:1 2.62 ± 0.06 2.57 ± 0.04 0.4261
17:1 0.27 ± 0.00 0.28 ± 0.00 0.0099
18:1 27.47 ± 0.17 28.48 ± 0.18 0.0001
20:1 0.05 ± 0.02 0.11 ± 0.02 0.0061
24:1 Tr ND 0.3215
PUFA Total 15.02 ± 0.79 13.83 ± 0.74 0.2763
18:2ω6 11.65 ± 0.74 11.87 ± 0.68 0.8728
18:3ω6 Tr Tr 0.3566
20:2ω6 Tr Tr 0.5027
20:3ω6 0.16 ± 0.02 0.17 ± 0.02 0.9043
20:4ω6 0.09 ± 0.01 0.14 ± 0.01 <0.0001
18:3ω3 1.90 ± 0.09 1.29 ± 0.09 <0.0001
20:3ω3 Tr ND 0.3215
20:5ω3 0.04 ± 0.00 ND <0.0001
22:6ω3 Tr Tr 0.9031
CLA Total 1.17 ± 0.04 0.35 ± 0.03 <0.0001
CLA c9t11 1.12 ± 0.04 0.35 ± 0.03 <0.0001
CLA (other) 0.05 ± 0.01 Tr <0.0001
ω6:ω3 5.78 ± 0.27 9.39 ± 0.45 <0.0001
1 x ± SEM as g/100g identified FAME  2 CLA vs Control
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Chapter IV:  General Conclusions
Discussion
The study presented in Chapter III does not provide an optimistic view of products 
from pasture-fed as compared with grain-fed cattle.  While the narrow focus of the 
experiment was to investigate the effects of CLA on markers of health, the other 
differences in fatty acid contents in the administered diets cannot be ignored, and 
thus this discussion will try to expand on the characteristics of the presented study in 
terms of the larger picture of diet, health, and agriculture.
The discussion presented in Chapter III detailed a number of potential short comings 
of the study, including the duration of the study, the differences in fatty acid 
compositions besides CLA, and the small difference in macronutrient composition. 
The relatively short duration of the presented study limits the conclusions that can be 
drawn.  As mentioned, there is a potential for more chronic effects of CLA on health, 
and 8 weeks may not be long enough to elucidate these effects.  On the other hand, 
the improvements in the fatty acid profile of the CLA diet, such as the improved 
ω3:ω6 fatty acid ratio and decreases in oleic and palmitic acids, should have had 
synergistic effects with CLA if CLA  indeed improves markers of health.  However, 
the high CLA diet did not result in any measurable improvements in health, in spite 
of the other improvements to the fatty acid profiles.  Another consideration is that the 
modest discrepancy between the macronutrient compositions of the two diets could 
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have been enough to alter the responses of the participants such that the CLA diet 
was ineffective.  This is not likely, however, because the carbohydrate, protein, and 
total energy intake approximations did not differ between the two diets, indicating 
that the difference in lipid content did not result in lower energy intake, which further 
indicates that the difference in calories from lipids was divided among the other two 
macronutrients, effectively mitigating any direct substitution of one macronutrient for 
another.  In addition, the composition of the CLA diet could almost be seen as biased 
to produce beneficial results: lower lipid content, a trend toward a decreased total 
energy intake with p~0.1, as well as lower, though not statistically significant, 
cholesterol consumption, in addition to the increased content of CLA and overall 
improved fatty acid profile .  Yet, no positive effects of CLA in this natural matrix were 
seen.
Whigam and colleagues have argued that many of the studies reporting no effects of 
CLA on body composition and other factors is the result of insufficient power(42).  In 
their meta-analysis, they indicate that a 12 week study would require 44 subjects on 
a CLA supplement and another 44 on a placebo to detect a significant decrease in 
body fat mass according to their regression equation.  However, their meta-analysis 
was based primarily on ad-libitum, pill-supplemented CLA research, which inherently 
results in a greater variability in responses and, further, includes other confounding 
factors, such as the uncontrolled energy intake of participants.  While ad-libitum 
studies are important for the clinical application of any treatment or supplement, the 
efficacy of CLA versus a placebo on body composition would almost certainly 
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depend on energy intake, food choices, food matrix, and a host of other factors 
uncontrolled in supplementation to free-living participants.  In fact, the only study to 
date to be conducted in a metabolic ward in an attempt to control all confounding 
variables reports that CLA has no effects on women(86), which corresponds with the 
conclusions of the study presented in Chapter III.  Thus, the clinical and 
experimental effects of CLA are likely vastly different.
Expanding beyond just the CLA content of the diets, advocates of pasturing cattle 
cite a number of studies that show improved fatty acid profiles of products from 
pasture-fed cattle(17)(16); the alleged improvement is based on other studies that 
indicate fatty acid saturation(89), ω3:ω6 ratios(90), CLA(42), and other fatty acids 
alter health.  The conclusion that products from pasture-fed cattle improve health 
because of improved fatty acid profiles is thus at least once removed from the 
scientific evidence.  In Chapter III, for the first time evidence was presented 
indicating consuming beef and dairy products from pasture-fed cattle does not result 
in improvements in select measures of health over beef and dairy products from 
grain-fed cattle.  However, the lack of evidence of an effect was in a short term 
study, in energy-controlled dietary intake, and specifically in a group of young, 
healthy women.  Thus, other research is necessary to more accurately determine 
the effects of CLA and products from pasture-fed cattle on human health.
Future Research
The conclusions of the study presented in Chapter III are limited in their scope.  To 
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expand the scope of conclusions, other populations must be examined.  In particular, 
the same study conducted on males, post-menopausal women, and individuals with 
relevant disorders such as diabetes and familial hypercholesterolemia, would be 
important in expanding the characterization of beef and dairy products naturally 
enriched in CLA in a controlled and restricted feeding setting.
Tricon and colleagues have investigated the effects of products from dairy cattle 
forced to produce higher concentrations of CLA by supplementing the cattle with 
oils(18).  They claimed that the dairy products were simply enriched with c9,t11, but 
other research has indicated that subjecting the rumen to those conditions results in 
rumen dysfunction, and thus increased production of the t10,c12 isomer of CLA(12). 
Therefore, a study in which individuals were asked to substitute products of pasture-
fed origin for their usual consumptions of conventional products in an ad-libitum 
manner would not only be a more natural way to determine the effects of higher 
concentrations of CLA in ruminant products in normal consumption patterns, but may 
also decrease the amount of the t10,c12 isomer of CLA in the products.  The 
exclusion of t10,c12 CLA is of importance because of the potential for isomer-
dependent effects of CLA on health(91).  Again, these studies would have to be 
conducted on a variety of populations because of the evidence for the correlation of 
sex with the effects of CLA(41).
By conducting these two types of studies (that is, the controlled, isocaloric studies 
versus the ad-libitum supplementation studies), a wider array of conclusions may be 
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drawn.  For instance, the effects of CLA supplementation of products from pasture-
fed cattle could be analyzed to determine if sex effects the response to CLA.  Also, 
determining the difference in controlled intake versus ad-libitum intake of the same 
products would provide insight into the mechanisms of action for the purported 
health effects of CLA; as an example, if differences exist between studies that 
supplement free-living humans and studies that control food intake, CLA may effect 
total energy consumption rather than effecting metabolism.
Conclusions
CLA research has yet to adequately define the variables that determine whether or 
not consumption of CLA results in improved or impaired biomarkers of health. 
Isomeric, sex, body compositional, supplementation method, and other effects may 
or may not play a role in the effects of CLA on health.  Even less well defined than 
the effects CLA has on health are the effects that products from pasture-fed animals 
have on health.  With the burgeoning pasture-fed industry, it is imperative to 
determine the human health effects, or lack there of, that these products possess. 
Thus, the conclusion of this thesis can only be that CLA does not uniformly effect 
various populations, and much more research must be conducted.
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Appendix A: Acute effects of sucralose
Introduction
Empirical observations in Iowa State University's Human Metabolic Unit (HMU) 
indicate that individuals on full feeding studies in which consumption patterns are 
entirely dictated by the study quickly become resentful of the lack of options for food, 
even when the menus are relatively varied.  Thus, the longer the study, the more 
unrest, which is more likely to lead to non-compliance.  Some of the unrest appears 
to be the result of seemingly stagnant eating patterns, while a larger portion appears 
to be the result of control; that is, the participants begin to resent not being able to 
select their own foods and beverages.  However, to provide participants with options 
introduces unwanted variability, especially if the options are caloric in nature.  This 
added variability must be weighed against the potential for non-compliance in 
determining if and what options should be made available to participants.
Much anecdotal evidence exists indicating that consumption of artificial sweeteners 
increases the desire to consume carbohydrates, increases hunger, causes 
exhaustion, impairs feelings of wellness, and causes a number of other maladies, 
with little scientific evidence to support these claims when sweeteners are consumed 
as directed.  While it is not disputed that some individuals may have a sensitivity to 
these artificial sweeteners(92)(93), there is a lack of scientific evidence that these 
problems occur on a large scale(94).  Further, the most popular research used to 
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combat the use of artificial sweeteners is either epidemiological or conducted in 
animal models, of which neither can make mechanistic or causal conclusions for the 
average human population.  In a recent animal study, researchers at Purdue 
indicated that artificial sweeteners may alter the body's ability to determine the 
caloric values of food on the basis of taste alone(95).  However, the study was 
conducted in rats using saccharin as the artificial sweetener.  Rats prefer saccharin 
over sugar, and also prefer saccharin over sucralose, another artificial 
sweetener(96)(97), therefore making the conclusions of the Purdue research highly 
speculative.  Further, a study in which groups of humans were supplemented with a 
mix of acesulfame K, aspartame, cyclamate, and saccharin, versus sucrose for 10 
weeks resulted in the artificial sweetener group not altering food intake, whereas the 
sucrose supplement resulted in weight and body fat mass gain(98).
Of the most popular artificial sweeteners on the market today, sucralose is generally 
attributed the most promising record.  Sucralose is stable at most temperatures and 
pHs, unlike its largest competitor aspartame, which allows for sucralose to be 
reliably used as a sweetening agent in acidic soft drinks, hot beverages such as tea 
and coffee, on breakfast cereals, and in baked goods(99).  These characteristics 
make it an ideal choice for controlled calorie studies to provide variety to the 
participants.  Aspartame, another popular artificial sweetener, is less stable, 
especially at elevated temperatures, making it a more limited choice.  Further, 
anecdotal accounts from participants at the HMU gave the impression that 
aspartame carries more of a negative reputation among participants, which relates 
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well to controlled research(100).  
Fasting glucose in type II diabetics over a 13 week period did not change in subjects 
supplemented with sucralose versus a control(101), which encourages its use in 
studies that include glucose measurements.  However, to the best of our knowledge, 
no evidence to date exists on the effects of an acute oral dose of sucralose on 
glucose homeostasis, especially in normal humans.  Further, because of the 
epidemiological and animal study data implicating artificial sweeteners as altering 
eating patterns, it is important to test the effects of sucralose on hunger: if the 
artificial sweetener makes a participant more or less hungry, compliance could be 
compromised.  An ideal artificial sweetener for use in calorie-controlled studies 
would have no effects on energy homeostasis, on qualitative assessments of well-
being, nor on hunger hormones.  Thus, the present study aims to determine the 
effects of sucralose in the form of Splenda®   (McNeil Nutrionals; Ft. Washington, 
PA) on glucose homeostasis and hunger in normal young females against water, 
sucrose, and sucrose combined with sucralose.  Further, the effects of consuming 
these beverages prior to consumption of a standardized breakfast will be 
determined.
Materials and Methods
Study design
The study was designed as a complete factorial; the four treatments were 12 oz of 
water (Control), 50 g sucrose dissolved in 12 oz of water (Sucrose), 6 g of Splenda 
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dissolved in 12 oz of water (Splenda), and 50 g of sucrose plus 6 g of Splenda 
dissolved in 12 oz of water (Both).  Treatments were based loosely on a typical 
single serving of soft drink.  McNeil Nutritionals indicated that granular Splenda 
contains 6-8% sucralose by weight, and sucralose is 500-750 times sweeter than 
sucrose(100).  Based on these assumptions, a range of Splenda drinks were 
designed, and an ad hoc blind taste panel was used to determine what Splenda 
content would approximate 50 g of sucrose (data not shown).  The results of the 
taste panel indicated that the Splenda and Sucrose treatments, as defined above, 
were similar in sweetness, Control was much less sweet, and Both was much 
sweeter.
Participants were asked to not eat or drink anything except for water after 9 PM the 
night before the study.  Participants arrived at the HMU at 7 AM.  A Visual Analogue 
Scale (VAS) test was administered assessing hunger, tiredness, gastrointestinal 
well-being, and overall well-being.  An intravenous catheter was inserted into each 
participant’s arm by a registered trained nurse and a fasting blood sample was 
drawn.  Participants were then given a treatment beverage to consume within 5 min 
of administration.  At 30 and 60 min after finishing the beverage, the participants 
were administered another VAS and another blood sample was drawn immediately 
thereafter.
At 60 min, a breakfast was administered consisting of scrambled eggs with cheese, 
orange juice, and buttered whole wheat toast.  The breakfast was designed using 
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Nutritionist Pro (version 2.3, First DataBank, Inc.; San Bruno, CA) to contain 500 
kcal, of which 15.7% were protein, 46.6% were carbohydrate, and 37.7% were lipid, 
which approximates the average composition consumed by females age 20-40 y in 
the United States(81).  The participants were asked to consume the breakfast in 15 
min or less.  At 30, 60, 90, and 120 min after finishing consumption of the breakfast, 
another VAS was administered and another blood sample was taken.  The catheter 
was then removed, concluding the participation for that day.  The same protocols 
were repeated to administer each treatment to each participant on each of four 
separate days of participation, resulting in a four arm cross over design.
Human Participants
Research was approved by the Iowa State University Institutional Review Board.  All 
individuals who were screened signed an informed consent document.
Women between the ages of 20 and 27, with a body mass index between 19 and 30, 
not pregnant or nursing, non-smoking, non- to moderate-drinkers, non-diabetic, who 
considered themselves in good health, were invited to be screened for participation. 
Screening included a measurement of height, weight, and a medical history 
questionnaire.  The eight women who were closest in age and BMI were asked to 
participate.  Participants had a mean BMI of 22.16 ± 1.71 kg/m2 and a mean age of 
21.75 ± 2.25 y (means ± SD).
One participant had an adverse event to the insertion of the IV and was unable to 
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complete one of the treatments; treatment sequence was thus rearranged to 
complete the Control, Sucrose, and Sucralose treatments.  Other missing data 
points were the result of IV difficulties, a participant being unexpectedly called away 
during the last timepoint, or from sample loss related to equipment error.  Of 224 
samples expected to be collected (8 participants x 4 days x 7 timepoints), 209 were 
collected successfully.  The missing data points were found to be unrelated to any 
one treatment.
VAS
A line 100 mm in length was placed neutrally between two extremes in an effort to 
quantify subject feelings.  Phrasing was intended to represent equally intense 
extremes at each end; further, phrases containing similar numbers of characters 
were constructed in an attempt to reduce anchoring based on the visual size of the 
phrase.  Participants were asked to place a mark on the line between the two 
extremes that represented their feeling at that time.  VAS scores were quantified by 
measuring from the left end of the mark to the line drawn by the participant to the 
nearest mm.
Blood analysis
Blood samples were kept on ice until plasma was separated by centrifugation at 
3000 x g for 15 min at 4 ºC.  An aliquot of plasma was treated with 10 µl 
phenylmethylsulfonyl flouride (PMSF, Sigma; St. Louis, MO) in methanol and 50 µl of 
1 N hydrochloric acid for every 1 mL of plasma prior to storing in a plastic microfuge 
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tube for analysis of ghrelin active.  Another aliquot was treated with 50 µl of 5500 
KIU/mL aprotinin (Sigma) and stored in a glass tube for analysis of glucagon. 
Unaltered aliquots of plasma were placed in plastic microfuge tubes for analysis of 
triacylglycerols (TAG), glucose, and insulin.  Samples were stored at -20 ºC until 
analyzed.  Glucose and TAG were assayed by colorimetric enzymatic assay (Kits 
G7521 and T7532, respectively, Pointe Scientific; Canton, MI).  Ghrelin active, 
insulin, and glucagon concentrations were assayed by radioimmunoassay 
(GHRA-88HK, HI-11K and GL-32K, respectively, Linco Research; St. Charles, MO).
Statistics
The Mixed procedure of SAS (version 9.1, SAS Institute Inc.; Cary, NC) was used to 
account for missing data.  Day of participation, subject, treatment drink, timepoint, 
and treatment sequence were used as classification variables, whereas treatment 
drink, timepoint, sequence of treatment, day, and the interaction of treatment and 
timepoint were fixed effects.  Subject-within-sequence was used as a random effect. 
No significant differences existed among treatment sequences so response 
variables within timepoint were averaged by least squares means for each treatment 
across subjects for graphical representations.  Individual timepoints were compared 
across treatments and against timepoint 0 (baseline) within treatment.  Statistical 
significance was considered at p<0.05.
Results
Blood analytes
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Glucose metabolism, as measured by glucose (Figure 11), insulin (Figure 12), and 
glucagon (Figure 13) concentrations, reflected the relative metabolic inertness of 
Splenda.  Between the treatment drinks and breakfast, the Splenda treatment 
resulted in glucose concentrations slightly higher than the Control treatment but not 
different from baseline.  While Sucrose resulted in significantly elevated glucose 
concentrations as compared with both baseline and Control, the combination 
treatment resulted in glucose concentrations similar to Splenda alone.  As expected, 
after the breakfast was consumed, glucose concentrations surged in the Control and 
Splenda groups, which corresponds to the lower insulin concentrations prior to 
consumption of breakfast; that is, the fact that insulin was not stimulated by the 
beverage means that glucose clearance was not already stimulated, unlike the 
Sucrose and Both groups.  However, within an hour after breakfast consumption, the 
glucose concentrations once again converged on a similar value, as had happened 
prior to breakfast across all groups.  Ninety minutes after breakfast, the glucose 
concentrations were significantly different between the Sucrose and Splenda groups, 
even though the Splenda glucose concentrations did not differ from baseline or 
Control.  All concentrations once again converged to a similar value after 120 min 
with the exception of the Both group.
Insulin concentrations increased significantly in the Both and Sucrose treatments 
above baseline and as compared with the Control after consumption of the 
beverage, as expected from the glucose content.  The small but significant increase 
in insulin concentrations in the Splenda group as compared with the control 30 min 
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after the treatment drink was consumed (but not from baseline) may likely be caused 
by the maltodextrin used in Splenda to emulsify sucralose, though other 
explanations, such as a cephalo-pancreatic response, cannot be ruled out by these 
data.  After consuming breakfast, the insulin concentrations of all groups increased 
above baseline, not differing from one another.  No differences between treatments 
within timepoints were observed after the consumption of the breakfast.
Unlike glucose and insulin, glucagon concentrations do not present any clear 
differences among treatments.  At 30 min after consuming the treatment, glucagon 
concentrations in the Splenda group were higher than the Control, but not different 
from baseline or any other treatments; at 60 min, glucagon concentrations from the 
Sucrose-group were significantly lower than the Control, though not different from 
baseline or any other treatment.  Though the two differences exist at 30 and 60 min, 
no samples were different from baseline, indicating no great changes in 
concentrations.  After consumption of breakfast, glucagon concentrations increased 
until they were greater than baseline for each treatment after 90 min; at 60 min after 
breakfast, those that consumed the Both treatment had glucagon concentrations 
greater than the Control and baseline, but not different from any other treatment.
TAG concentrations did not vary among treatments before breakfast (Figure 14). 
The only change before breakfast was the decrease in TAG concentrations below 
baseline within the Both group 60 min after drink consumption.  The Both group 
remained lower than baseline until 90 min after breakfast, at which point 
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concentrations did not differ from baseline through 120 min.  Also at 90 min after 
breakfast, the Sucrose group had lower TAG concentrations as compared with the 
Control group, though no treatments differed from baseline, nor did the Sucrose 
group differ from the other two treatments at that timepoint.
Ghrelin active concentrations decreased below baseline upon consumption of Both 
and Sucrose drinks, and concentrations were also significantly lower than those who 
consumed Splenda and Control drinks (Figure 15).  This reflects the lack of effect of 
Splenda and the Control on the stimulation of the active form of ghrelin.  After 
consumption of breakfast, the ghrelin active concentrations of the Splenda and 
Control groups declined in a manner similar to the decline seen in the Sucrose and 
Both groups upon consumption of the treatment drink.  At 30 min, the Splenda group 
had higher ghrelin active than did the Sucrose or Both groups, but not different from 
the Control; after 60 min, the concentrations among groups converged through the 
end of the timecourse.
VAS
Feelings of gastrointestinal well-being (Figure 16) were similar throughout the entire 
timecourse among all treatments.  Before consuming breakfast, no differences were 
noted against baseline nor among treatments.  After breakfast, the stomach feeling 
generally improved, with all treatments increasing above baseline through 90 min, 
and the Control and Sucrose groups remaining improved through 120 min.
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The measurement of hunger resulted in a difference among treatments at baseline 
(Figure 17).  This difference, however, dissipated through 30 and 60 min after 
consuming the treatment drink.  The Splenda and Control groups were significantly 
more hungry from baseline at 60 min, which corresponds with the ghrelin active 
data, and which is expected with no caloric consumption against the Sucrose and 
Both groups.  After consuming breakfast, all participants remained less hungry than 
baseline through the end of the timecourse.  Those consuming Sucrose remained 
fuller as compared with those consuming Both, but neither treatment was different 
from Control or Splenda.
Participants did not experience any immediate changes in feelings of consciousness 
as measured by how sleepy or awake they felt (Figure 18).  Thirty min after 
participants consumed breakfast, those who consumed Splenda or Both felt more 
awake than did the individuals who consumed Sucrose, and the Splenda group felt 
more awake than before consuming the beverage.  However, Splenda, Sucrose, nor 
Both deviated from the Control.  At 60 min, participants converged on a similar 
feeling of alertness, though 90 and 120 min after breakfast the groups returned to 
the relative states they were in at 30 min after breakfast with the addition of Control 
being elevated above baseline.
Overall, participants' perceptions of general well-being did not change much 
throughout the study (Figure 19).  Those on the Sucrose treatment generally felt 
worse than those on the Splenda treatment, but when the significant difference at 
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baseline is accounted for, much of this effect is negated.  However, besides 
baseline, only at 90 min did those on Sucrose feel significantly worse than those on 
the Control.  Throughout the timecourse, those on the Sucrose and Splenda 
treatments improved their perception of overall well-being against baseline, though, 
again, the more unpleasant feelings at baseline of Sucrose makes this effect 
questionable for the Sucrose group.  Those on Control or Both did not change 
throughout the timecourse against baseline.
Discussion
The present study was designed to determine if consumption of an approximate soft 
drink's equivalent of Splenda would result in any noticeable metabolic changes or 
qualitative changes in feelings of well-being against an equivalent of water, sucrose, 
or a combination of sucrose and Splenda.  Thus, the water acted as a negative 
control, sucrose as a positive control, and the combination to determine if any 
synergistic effects between sugar and sucralose exist.  By administering the 
treatment drinks in a fasted state, the first hour of the timecourse resembled an oral 
glucose tolerance test; additionally, subsequent feeding of a breakfast resembles an 
average pre-meal beverage, such as a mid-afternoon soft drink prior to dinner.
Besides presenting a different aspect of glucose metabolism data within this study, 
the first data on the effects of artificial sweeteners on ghrelin in humans is presented 
and only the second to investigate the effects of an artificial sweetener on ghrelin at 
all(97).  The other study is, in essence, the opposite of the presented study: instead 
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of supplementing the sweetener and measuring hormones, orexigenic 
neuropeptides were administered to rats and consumption patterns of a saccharin-
water solution was monitored versus only a water solution.  Regardless of the study 
design or the model, a direct relation between ghrelin and saccharin was not found 
there, nor were ghrelin concentrations and sucralose consumption related here.
Though the present study did not measure ad-libitum food intake of the participants, 
the responses indicated that participants' hunger was unaffected by Splenda when 
compared with water, both in terms of ghrelin as a stimulant of hunger and the VAS 
data indicating fullness.  Therefore, no alterations in food intake would be expected. 
This extrapolation is supported by research on other artificial sweeteners over a 
longer term(98).
In general, those consuming the Splenda treatment responded in a manner similar 
to the Control, whereas Sucrose responded more similarly to Both.  This cursory 
assessment indicates that Splenda should be a relatively safe option for controlled 
energy studies to provide a break from the inherent redundancy of such studies. 
However, the limitations of this study are that it was conducted in free living 
individuals with no lifestyle directions except pre-study fasting; the exposures to 
each treatment and the responses were acute; and the study was limited to young, 
healthy females.  Thus, more research must be conducted to expand the claim that 
sucralose is safe for use in controlled experiments.
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Figure 11.  Glucose concentrations
Plasma glucose concentrations were quantified colorimetrically (Mean±SEM). 
Baseline concentrations (BL) were quantified, followed by administration of a 
treatment drink.  Drink completion time is marked by the 'Drink' dotted line.  All 
treatment groups had increased glucose concentrations compared with the Control 
at 30 min, but concentrations converged at 60 min.  After 60 min, breakfast was 
served; breakfast completion time is marked by the 'Bfast' dotted line.  The Sucrose 
and Both treatments prevented the postprandial surge in glucose concentrations, 
whereas the Control and Splenda treatments experienced postprandial surges in 
glucose; again, concentrations converged after 60 min.  Datapoints within a 
timepoint without common letters differ significantly; * denotes a datapoint differs 
significantly from baseline; ε indicates all datapoints within a timepoint are different 
from baseline.  p<0.05 is considered significant.
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Figure 12.  Insulin concentrations
Plasma insulin concentrations were quantified by radioimmunoassay (Mean±SEM). 
Baseline concentrations (BL) were quantified, followed by administration of a 
treatment drink.  Drink completion time is marked by the 'Drink' dotted line.  Sucrose 
and Both treatments increased concentrations above baseline through 60 min, 
whereas Splenda and Control treatments did not, though Splenda increased insulin 
above Control at 30 min.  After 60 min, breakfast was served; breakfast completion 
time is marked by the 'Bfast' dotted line.  All treatments converged, and were all 
above baseline through 60 min after breakfast.  Datapoints within a timepoint without 
common letters differ significantly; * denotes a datapoint differs significantly from 
baseline; ε indicates all datapoints within a timepoint are different from baseline. 
p<0.05 is considered significant.
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Figure 13.  Glucagon concentrations
Plasma glucagon concentrations were quantified by radioimmunoassay 
(Mean±SEM).  Baseline concentrations (BL) were quantified, followed by 
administration of a treatment drink.  Drink completion time is marked by the 'Drink' 
dotted line.  Splenda treatment elevated glucagon concentrations above Control at 
30 min, and Sucrose resulted in decreased glucagon as compared with Control at 60 
min, though no treatments differed from baseline.  After 60 min, breakfast was 
served; breakfast completion time is marked by the 'Bfast' dotted line.  The Both 
treatment increased glucagon above Control and baseline concentrations at 60 min, 
but converged with the other treatments above baseline at 90 and 120 min. 
Datapoints within a timepoint without common letters differ significantly; * denotes a 
datapoint differs significantly from baseline; ε indicates all datapoints within a 
timepoint are different from baseline.  p<0.05 is considered significant.
40
60
80
100
120
140
BothSplendaControl Sucrose
D
rin
k 30 60
B
fa
st 30 60 90 12
0
B
L
b
G
lu
ca
go
n 
(p
g/
m
L)
b
b
a
a
a
ab
ab
ab
ab
ab
ab
*
ε
ε
83
Figure 14.  TAG concentrations
Plasma TAG concentrations were quantified colorimetrically (Mean±SEM).  Baseline 
concentrations (BL) were quantified, followed by administration of a treatment drink. 
Drink completion time is marked by the 'Drink' dotted line.  The Both treatment 
caused a decrease in TAG at 60 min below baseline, but did not differ from other 
treatments.  After 60 min, breakfast was served; breakfast completion time is marked 
by the 'Bfast' dotted line.  The Both treatment remained below baseline through 60 
min; only at 90 min did two treatments differ, with Sucrose decreasing below Control. 
Datapoints within a timepoint without common letters differ significantly; * denotes a 
datapoint differs significantly from baseline.  p<0.05 is considered significant.
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Figure 15.  Ghrelin active concentrations
Plasma ghrelin active concentrations were quantified by radioimmunoassay 
(Mean±SEM).  Baseline concentrations (BL) were quantified, followed by 
administration of a treatment drink.  Drink completion time is marked by the 'Drink' 
dotted line.  Sucrose and Both treatments decreased below baseline, with only 
Sucrose decreasing below Control, at 30 min.  At 60 min, Splenda and Control 
differed significantly from Sucrose and Both, but not each other, and vice versa. 
After 60 min, breakfast was served; breakfast completion time is marked by the 
'Bfast' dotted line.  Sucrose and Both treatments, and Splenda and Control 
treatments, remained similar at 30 min, after which all four treatments converged to 
similar concentrations.  Datapoints within a timepoint without common letters differ 
significantly; * denotes a datapoint differs significantly from baseline.  p<0.05 is 
considered significant.
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Figure 16.  VAS responses for gastrointestinal well-being
VAS scores to determine how the participants' GI tracts felt were measured to the 
nearest millimeter (Mean±SEM).  Baseline values (BL) were determined, followed by 
administration of a treatment drink.  Drink completion time is marked by the 'Drink' 
dotted line.  After 60 min, breakfast was served; breakfast completion time is marked 
by the 'Bfast' dotted line.  No treatments differed from each other throughout the 
timecourse, and only differences from baseline were observed.  * denotes a 
datapoint differs significantly from baseline; ε indicates all datapoints within a 
timepoint are different from baseline.  p<0.05 is considered significant.
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Figure 17.  VAS responses for hunger
VAS scores to determine hunger were measured to the nearest millimeter 
(Mean±SEM).  At baseline (BL), the Sucrose treatment group felt hungrier than the 
Control and Splenda groups.  After BL, a treatment drink was administered; drink 
completion time is marked by the 'Drink' dotted line.  For the next 60 min, all four 
treatment groups were not significantly more or less hungry than each other.  After 
60 min, breakfast was served; breakfast completion time is marked by the 'Bfast' 
dotted line.  All participants became much fuller after consumption of breakfast as 
compared with baseline; the Sucrose treatment maintained fullness longer as 
compared with the Both group at 90 and 120 min.  Datapoints within a timepoint 
without common letters differ significantly; * denotes a datapoint differs significantly 
from baseline; ε indicates all datapoints within a timepoint are different from 
baseline.  p<0.05 is considered significant.
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Figure 18.  VAS responses for tiredness
VAS scores to determine degree of consciousness were measured to the nearest 
millimeter (Mean±SEM).  Baseline values (BL) were determined, followed by 
administration of a treatment drink.  Drink completion time is marked by the 'Drink' 
dotted line.  After 60 min, breakfast was served; breakfast completion time is marked 
by the 'Bfast' dotted line.  Those on the Sucrose treatment generally reported being 
sleepier than the Splenda and Both treatments after breakfast, though no treatment 
groups differed from the Control.  Datapoints within a timepoint without common 
letters differ significantly; * denotes a datapoint differs significantly from baseline; ε 
indicates all datapoints within a timepoint are different from baseline.  p<0.05 is 
considered significant.
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Figure 19.  VAS responses for overall well-being
VAS scores to determine overall feelings of wellbeing were measured to the nearest 
millimeter (Mean±SEM).  Baseline values (BL) were determined, followed by 
administration of a treatment drink.  Drink completion time is marked by the 'Drink' 
dotted line.  After 60 min, breakfast was served; breakfast completion time is marked 
by the 'Bfast' dotted line.  Those on the Sucrose treatment generally reported feeling 
less well than the Splenda treatment throughout the full timecourse; however, when 
the difference at baseline was taken into consideration, the Sucrose group reverted 
to being not different from the other treatments.  Datapoints within a timepoint 
without common letters differ significantly; * denotes a datapoint differs significantly 
from baseline; ε indicates all datapoints within a timepoint are different from 
baseline.  p<0.05 is considered significant.
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Appendix B: Menus for the CLA study
Monday
Breakfast
Pineapple juice 8 oz can
Cheerios 1 self-serve bowl (19 g)
Sugar 1 packet (1/10 oz)
Skim milk 10 oz carton 
Bran muffin 1
Raisins 1 0.5 oz box
Lunch
Taco
Flour tortilla 1 (64 g)
Ground beef 56 g
Taco seasoning mix 1 tsp
Cheddar cheese, shredded 42 g
Tomato, diced 45 g
Lettuce, shredded ~28 g
Salsa 2 oz 
Tortilla chips 28 g
Chocolate chip oatmeal cookies 2
Dinner
Pizza
7” Mama Mary's crust 1
Butter 5g
Ground beef 28 g
Pizza sauce 120 g
Green pepper 10 g
Onions 10 g
Cheddar cheese, shredded 42 g
Orange 1 (~131 g)
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Tuesday
Breakfast
Orange Juice 8 oz or 250g
Oatmeal 35 g dry
Raisins 0.5 oz box
Brown Sugar 5 g
Skim milk 10 oz carton 
Raspberry muffin 1
Lunch
Sloppy Joe
Ground beef 28 g
Onion 10 g
Green pepper 10 g
Manwich mix 20 g
Bun 1
Corn, frozen 85 g
Butter 10 g
Dill pickle 40 g
Peaches 4 oz cup
Grapes 80 g
Chocolate chip cookies 2
Dinner – set out chopped chives
Meat loaf
Ground beef 56 g
Oatmeal 15 g
Onions, chopped 10 g
Catsup 1 Tbsp
Mashed potato 200 g
Butter 25 g
Pineapple tidbits 4 oz cup
Premium vanilla ice cream 66 g
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Wednesday
Breakfast
Juicy Juice 1 box (6.75 oz)
Raisin Bran cereal 1 self-serve bowl (35 g)
Sugar 1 packet (1/10 oz)
Skim milk 10 oz carton
Banana 1 (~118 g)
Blueberry muffin 1
Lunch
Cheese burger
Small bun 1
Butter 5 g
Ground beef 56 g
Cheddar cheese, sliced 42 g
Tomato, sliced 45 g
Lettuce, leaves ~28g
Tortilla chips 28g
Salsa 2 oz 
Chocolate chip oatmeal cookies 2
Dinner
Spaghetti
Ground beef 56 g
Butter 5 g
Spaghetti sauce 112 g
Parmesan cheese 10 g
Spaghetti, cooked 160 g
Pillsbury crusty French roll 1
Butter 15 g
Looseleaf lettuce ~56 g
Italian dressing 15 g
92
Thursday
Breakfast
Orange juice 8 oz or 250g
Cream of wheat, dry 35 g
Brown sugar 5 g
Skim milk 10 oz carton
Apple cinnamon raisin muffin 1
Lunch
Calico bean casserole
Ground beef 28 g
Red kidney beans 75 g
Baked beans, vegetarian 75 g
Butter beans 75 g
Brown sugar 20 g
Molasses 7.5 g
Mustard, dry 1/8 tsp
Pillsbury crusty sourdough roll 1
Butter 10 g
Grapes 80 g
Peanut butter cookie 1
Dinner
Fajita beef on mashed potato
Ground beef 56 g
Onion, chopped 10 g
Green pepper 10 g
Fajita seasoning 1 tsp
Potato 200 g
Butter 25 g
Carrots 45 g
Looseleaf lettuce 56 g
Ranch dressing 15 g
Orange 1 (~131 g)
Premium vanilla ice cream 66 g
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Friday
Breakfast
Orange juice 8 oz or 250g
Corn Flakes cereal 35 g 
Sugar 1 packet (1/10 oz)
Skim milk 10 oz carton
Bran muffin 1
Banana 1 (~118 g)
Lunch
Taco salad
Ground beef 56 g
Taco seasoning ½ tsp
Cheddar cheese, shredded 28 g
Tomato, chopped 85 g
Looseleaf lettuce 100g
Black olives 15 g
Salsa 2 oz
Tortilla chips 28 g
Chocolate chip cookies 2
Apple 1 (~125 g)
Dinner
Pizza
7” Mama Mary's Crust 1
Butter 5 g
Ground beef 28 g
Green pepper 10 g
Onions 10 g
Pizza sauce 120 g
Cheddar cheese 42 g
Orange 1 (~131 g)
Premium vanilla ice cream 66 g
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Saturday
Breakfast
Pineapple orange juice 8 oz can
Raisin bran cereal 1 self-serve bowl (35 g)
Sugar 1 packet (1/10 oz)
Skim milk 10 oz carton
Blueberry muffin 1 
Lunch
Cheesy beef rice
Ground beef 28g
Onion 10g
Green pepper 10g
Cooked rice  65g
Butter 5g
Peas, cooked and drained 40g
Cheddar cheese, shredded 28 g
Bread stick 1
Butter 10 g
Carrots 30 g
Celery 30 g
Kiwi 1
Fruit cup 1
Dinner
Spaghetti
Ground beef 56 g
Butter 5 g
Spaghetti sauce 112 g
Parmesan cheese 10 g
Spaghetti, cooked 160 g
Pillsbury crusty sourdough roll 35 g
Butter 15 g
Looseleaf lettuce ~56g
Italian dressing 15 g
Peanut butter cookies 2
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Sunday
Breakfast
Orange juice 8 oz carton
Cheerios 1 self-serve bowl (19 g)
Banana 1 (~118 g)
Sugar 1 packet (1/10 oz)
Skim milk 10 oz carton
Apple cinnamon raisin muffin 1
Lunch
Teriyaki noodle casserole
Ground beef 56 g
Onions 10 g
Butter 10 g
Teriyaki sauce 2 Tbsp
Egg noodles, cooked 160 g
Pillsbury crusty sourdough roll 1
Butter 15 g
Carrots 30 g
Apple 1 (~125 g)
Dinner
Lasagna
Ground beef 28 g
Spaghetti sauce 120 g
Cottage cheese 56 g
Cheddar cheese, shredded 28 g
Lasagna noodles, dry 42 g
Pillsbury wheat roll 35 g
Butter 15 g
Green beans 120 g
Looseleaf lettuce ~56 g
Italian dressing 15 g
Chocolate chip cookie 1
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Appendix C:  Recipes for the CLA study
Apple Cinnamon Raisin Muffins
140 g Brown Sugar
280 g Flour
11 g Baking Powder
2.5 g Nutmeg
5 g Ground Cinnamon
160 g Apple Juice
100 g Chopped Apple
80 g Raisins
160 g Butter
1 Egg
Preheat oven to 400 ºF.  Weigh large, empty bowl with rubber spatula.  
Stir together brown sugar, flour, baking powder, and nutmeg in pre-weighed bowl.  In 
medium bowl, combine egg, butter, and apple juice.  Whisk until blended.  In another 
bowl, toss together apples and cinnamon until evenly coated; stir in raisins.  Pour 
egg mixture over dry ingredients, scraping with the rubber spatula to transfer as 
much as possible, and fold lightly 3-4 times with the spatula to partially combine. 
Add apple mixture and distribute evenly using as few strokes as possible.
Weigh bowl, spatula, and batter.  Divide weight by 30.  Weigh batter into muffin cups 
and place in muffin pan.  Bake in middle of oven for 23-25 min or until tops are 
golden and spring back when lightly pressed.  Let cool in pan 2 min; ease onto wire 
rack to cool 15-20 min.  Package individually.
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Blueberry Muffins
150 g White Granulated Sugar
315 g Flour
120 g Butter
11 g Baking Powder
1 Egg
120 g Skim Milk
300 g Blueberries
Preheat oven to 400 ºF.  Weigh large, empty bowl with rubber spatula.
In pre-weighed bowl, toss together flour, sugar and baking powder.  In medium bowl, 
melt butter in microwave; whisk together egg, milk, and butter.  
Pour liquid ingredients over dry ingredients; scrape with rubber spatula to transfer as 
much as possible.  Fold lightly 3-4 times with the rubber spatula (mixture should not 
be perfectly smooth and will be quite dry).
Weigh bowl, spatula, and batter.  Divide weight by 27.  Weigh batter into muffin cups 
and place in muffin pan.  Add 10g of blueberries (about 5-6 large blueberries) to 
each muffin.  Bake in middle of oven until tops are golden and spring back when 
lightly pressed (about 35 min).  Let cool in pan 2 min; ease onto wire rack to cool for 
15-20 min.  Package individually.
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Bran Muffins
300 g White Granulated Sugar
1 Tbl Baking Soda
½ tsp Salt
170 g All-Bran Cereal
255 g Butter
57 g 100% Bran Cereal
350 g Flour
490 g 1% Buttermilk
1 c Tap Water
Preheat oven to 350 ºF.  Weigh large, empty bowl with rubber spatula.  
Pour boiling water over 100% bran cereal; set aside.  Cream butter in pre-weighed 
bowl; gradually add sugar, flour, buttermilk, salt, baking soda, and all-bran cereal. 
Add bran/water mixture to other ingredients, scraping with rubber spatula to transfer 
as much as possible.
Weigh bowl, spatula, and batter; divide batter weight by 50.  Weigh batter into muffin 
cups and place in muffin pan.  Bake 15 min or until tops spring back when touched. 
Cool 2-3 min in pan.  Ease onto wire rack and cool 15-20 min.  Package individually.
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Raspberry Orange Muffins
160 g Orange Juice
1 Egg
130 g White Granulated Sugar
150 g Raspberries
11 g Baking Powder
80 g Butter
280 g Flour
Preheat oven to 400 ºF.  Weigh large, empty bowl with rubber spatula.  
Toss together flour, baking powder, and sugar in pre-weighed bowl.  Melt butter in 
microwave; cool slightly.  In medium bowl, combine orange juice, butter, and egg. 
Whisk until blended.  Pour liquid over flour mixture, scraping to transfer as much as 
possible, and stir lightly to combine. Coarsely chop berries.  Add berries and 
distribute evenly using as few strokes as possible.  
Weigh bowl, spatula, and batter.  Divide weight of batter by 24.  Weigh batter into 
muffin cup and place in muffin pan.  Bake in middle of oven 25 min or until tops are 
golden and spring back when lightly pressed.  Let muffins cool in pans 2 min.  Ease 
onto wire rack to cool for 15-20 min.  Package individually.
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Chocolate Chip Cookies
120 g Butter
48 g Brown Sugar
96 g White Granulated Sugar
1 Egg
½ tsp Vanilla Extract
132 g Flour
½ tsp Salt
½ tsp Baking Soda
252 Semi Sweet Chocolate Chips (~128 g)
Preheat oven to 375 ºF.  Weigh large, empty bowl with mixing utensil.
Cream butter in pre-weighed bowl; gradually add sugars.  Beat in egg and vanilla. 
Combine dry ingredients and add to creamed mixture.  
Weigh bowl, utensil, and batter.  Divide weight of batter by 36.  Place weighed dough 
on small squares of parchment paper on cookie sheets; add seven chocolate chips 
to the top of each one.  Bake about 10 min.  Cool on wire rack.  Package 
individually.
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Chocolate Chip Oatmeal Cookies
120 g Butter
110 g Brown Sugar
96 g White Granulated Sugar
1 Egg
½ tsp Vanilla Extract
125 g All Purpose Flour
½ tsp Salt
½ tsp Baking Soda
252 Semi Sweet Chocolate Chips (~128 g)
40 g Oatmeal
Preheat oven to 375 ºF.  Weigh large, empty bowl with mixing utensil.
Cream butter in pre-weighed bowl with mixing utensil; gradually add sugars.  Beat in 
egg and vanilla.  Combine dry ingredients, except for chocolate chips, and add to 
creamed mixture.  
Weigh bowl, utensil, and batter.  Divide weight of batter by 36.  Place weighed dough 
on small squares of parchment paper on cookie sheet; add seven chocolate chips to 
each one.  Bake about 10 min.  Cool on wire rack.  Package individually.
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Peanut Butter Cookies
120 g Butter
110 g Brown Sugar
96 g White Granulated Sugar
1 Egg
250 g Peanut Butter
½ tsp Salt
½ tsp Baking Soda
½ tsp Vanilla
145 g Flour
Preheat oven to 375 ºF.  Weigh large, empty bowl with mixing utensil.
Beat butter until soft in pre-weighed bowl.  Gradually add sugars.  Beat in egg, 
peanut butter, salt, baking soda, and vanilla.  Add flour; mix well.
Weigh bowl, utensil, and batter.  Divide by 60.  Form weighed amount of dough into 
a ball and place on a small square of parchment paper.  Place on cookie sheet. 
Flatten in a grid pattern with a fork.  Bake 10 to 12 min.  Cool on wire rack.  Package 
individually.
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